NAME,DESCRIPTION,SEQAPASS,GENE_SYMBOLS,GENE_NAMES,GENE_URLS,AOP,EVENT,HIT_CALL,TOP,SCALED_TOP,AC50,LOGAC50,BMAD,MAXMED,MAXMED_UNITS,MAXMEDCONC,CUTOFF,FLAGS,MODLACC,MODLAC10,MODLACB,STOCK_CONCENTRATION,INTENDED_TARGET_FAMILY
ACEA_AR_agonist_AUC_viability,"Data from the assay component ACEA_AR_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,151.288252968289,5.630500729409326,23.863711826816374,1.37773799593651,8.95647120560566,128.839287053696,percent_activity,1.47712125471966,26.869413616817,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.2905630989907,1.2905630989907,1.25276429020009,20,cell cycle
ACEA_AR_antagonist_80hr,"Data from the assay component ACEA_AR_antagonist_80hr was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, measures of the cells for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,2.86989444588759,7.840209225117698,13.209965289845437,1.12090167647536,0.122016065451132,2.85986524216955,log2_fold_induction,1.47712125471966,0.366048196353396,,0.982488220356808,0.982488220356808,0.962735174465125,20,nuclear receptor
ACEA_AR_antagonist_AUC_viability,"Data from the assay component ACEA_AR_antagonist_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,146.880502244028,5.073455183515982,17.281137059112012,1.23757231466206,9.65026114229828,121.651566255331,percent_activity,1.47712125471966,28.9507834268948,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.021117540704,1.021117540704,0.898944617338055,20,cell cycle
ACEA_ER_AUC_viability,"Data from the assay component ACEA_ER_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,112.9462020378736,5.64731010189368,23.382455186069212,1.3688901106658524,5.860768439731081,112.94478050775723,percent_activity,2,20,,1.285489808922207,1.2771014845196424,1.2496096608905636,20,cell cycle
APR_HepG2_CellCycleArrest_72h_dn,"Data from the assay component APR_HepG2_CellCycleArrest_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",, , , ,,,Active,1.25232734006773,1.3505460508952958,17.307821137268036,1.23824239845765,0.0927274815425616,1.04360611693183,log2_fold_induction,1.69897000433602,0.927274815425616,"[""Borderline active"",""Borderline active""]",1.43969296239791,0.99739206186819,0.815989540221237,20,cell cycle
APR_HepG2_CellLoss_24h_dn,"Data from the assay component APR_HepG2_CellLoss_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,3.76494376141257,5.68703952276198,56.459851478542674,1.7517397313714,0.066202173316075,2.96832035066317,log2_fold_induction,2,0.66202173316075,,1.36393637420373,1.02675063543756,1.20015348558804,20,cell cycle
APR_HepG2_CellLoss_72h_dn,"Data from the assay component APR_HepG2_CellLoss_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,4.0808532209867,4.598769562784848,30.326353705268293,1.48182019597246,0.0887379366431112,2.55038386061644,log2_fold_induction,2,0.887379366431112,"[""Cell viability assay fit with gnls winning model"",""Cell viability assay fit with gnls winning model""]",1.13707147560492,0.765100832064619,0.890304426677226,20,cell cycle
APR_HepG2_MitoMass_24h_dn,"Data from the assay component APR_HepG2_MitoMass_24hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMass_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",, , , ,,,Active,2.09701832556583,4.214350174212757,55.1466948990142,1.74151948903128,0.0497589957853361,1.74751527139456,log2_fold_induction,2,0.497589957853361,,1.43606681207213,1.06956371234247,1.1667219248023,20,cell morphology
APR_HepG2_MitoMass_72h_dn,"Data from the assay component APR_HepG2_MitoMass_72hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMass_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",, , , ,,,Active,2.14250075158734,3.131169969321015,60.976001452676286,1.78515894177461,0.0684249265475657,1.7854172930872,log2_fold_induction,2,0.684249265475657,,1.67842501916687,1.46853304267275,1.47522455310944,20,cell morphology
APR_HepG2_MitoMembPot_24h_dn,"Data from the assay component APR_HepG2_MitoMembPot_24hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMembPot_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",, , , ,,,Active,1.08501847756157,1.3060744231404438,18.420950982003895,1.26531204690186,0.0830747818300165,1.13217978286728,log2_fold_induction,1.69897000433602,0.830747818300165,,1.43469206809154,1.09219773008294,0.950963318103062,20,cell morphology
APR_HepG2_MitoticArrest_24h_up,"Data from the assay component APR_HepG2_MitoticArrest_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MitoticArrest_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""arrest"".",,H3F3A,"H3 histone, family 3A",https://www.ncbi.nlm.nih.gov/gene/3020,,,Active,1.75631290961888,1.5934237303188548,59.98541891097026,1.77804569611556,0.110222590275308,1.46359409137079,log2_fold_induction,2,1.10222590275308,,1.85302042266137,1.5681027938087,1.46236611195054,20,cell cycle
APR_HepG2_MitoticArrest_72h_up,"Data from the assay component APR_HepG2_MitoticArrest_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MitoticArrest_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""arrest"".",,H3F3A,"H3 histone, family 3A",https://www.ncbi.nlm.nih.gov/gene/3020,,,Active,2.76631650581102,1.9493929696249461,17.833226558714948,1.2512299270156,0.141906560088972,2.62615839764,log2_fold_induction,2,1.41906560088972,,1.26500944542786,0.798997754258704,0.668228735733121,20,cell cycle
APR_HepG2_p53Act_24h_up,"Data from the assay component APR_HepG2_p53Act_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",NP_000537.3,TP53,tumor protein p53,https://www.ncbi.nlm.nih.gov/gene/7157,"[46,46]",,Active,1.5163964090755893,1.5603119118077922,58.91488884531215,1.770225062634931,0.09718546641861357,1.26366367432157,log2_fold_induction,2,0.9718546641861358,,1.8580561602477932,1.5525914844648778,1.4370688087178587,20,dna binding
APR_HepG2_P-H2AX_24h_up,"Data from the assay component APR_HepG2_P-H2AX_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_P-H2AX_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.",NP_002096.1,H2AFX,"H2A histone family, member X",https://www.ncbi.nlm.nih.gov/gene/3014,,,Active,1.62374366897152,1.9774507401457027,59.388704496648764,1.77370385169404,0.0821129768750588,1.35311972418348,log2_fold_induction,2,0.821129768750588,,1.7770248290907,1.52307334219297,1.45376651197433,20,dna binding
ATG_Ahr_CIS_dn,ATG_Ahr_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_001612.1,AHR,aryl hydrocarbon receptor,https://www.ncbi.nlm.nih.gov/gene/196,,,Active,2.165731653502154,2.1861133560846824,54.47424388617448,1.7361912108624682,0.19813534805724511,1.8047763779558292,log2_fold_induction,2.30102999566398,0.9906767402862255,,1.489103890026385,0.32891463827745504,-1.4446171538059103,20,dna binding
ATG_AP_1_CIS_up,"Data from the assay component ATG_AP_1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_AP_1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOS and JUN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.","NP_005243.1|NP_002219.1","FOS | JUN","FBJ murine osteosarcoma viral oncogene homolog , jun proto-oncogene","https://www.ncbi.nlm.nih.gov/gene/2353 , https://www.ncbi.nlm.nih.gov/gene/3725",,,Active,0.8696813292194243,1.449966348796894,79.05542988384731,1.8979317045984692,0.11995882938125292,0.8691661691772685,log2_fold_induction,2.30102999566398,0.5997941469062646,"[""Only one conc above baseline, active""]",1.9412857479402392,1.8790247194061154,1.7786471322381834,20,dna binding
ATG_chAR_XSP1_dn,ATG_chAR_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/422165,,,Active,2.1289571384069843,3.698905092069512,6.535862603673376,0.8153029139200635,0.19185471424787195,1.7741309488261843,log2_fold_induction,1.30102999566398,0.5755641427436159,,0.49219704185694735,0.49219704185694735,0.10025139322658161,2,nuclear receptor
ATG_chAR_XSP2_dn,ATG_chAR_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/422165,,,Active,0.9819384129517983,1.556745875471228,1.8813269830803598,0.27446428444247795,0.21025448628099835,1.0021876363799689,log2_fold_induction,1.30102999566398,0.6307634588429951,,0.3846891180098154,0.3846891180098154,-0.13907658452630323,2,nuclear receptor
ATG_chERa_XSP2_up,"The assay endpoint ATG_chERa_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/396099,,,Active,1.5575048518084587,2.015818813951742,3.029279021568883,0.4813392772769963,0.2575470971611746,1.3118416776682096,log2_fold_induction,1.30102999566398,0.7726412914835237,,0.4742339024498563,0.4742339024498563,-0.5133790199968922,2,nuclear receptor
ATG_DR4_LXR_CIS_dn,ATG_DR4_LXR_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,"NP_009052.3|NP_005684.2","NR1H2 | NR1H3","nuclear receptor subfamily 1, group H, member 2 , nuclear receptor subfamily 1, group H, member 3","https://www.ncbi.nlm.nih.gov/gene/7376 , https://www.ncbi.nlm.nih.gov/gene/10062",,,Active,1.722690592157401,2.912406615590453,26.09280679015319,1.4165207984528791,0.11830014277097414,1.6957239234746724,log2_fold_induction,2.30102999566398,0.5915007138548707,,1.3161868835101904,1.2077457050137868,1.0765008891473253,20,nuclear receptor
ATG_DR5_CIS_dn,ATG_DR5_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,"NP_000955.1|NP_001277145.1|NP_000957.1","RARA | RARB | RARG","retinoic acid receptor, alpha , retinoic acid receptor, beta , retinoic acid receptor, gamma","https://www.ncbi.nlm.nih.gov/gene/5914 , https://www.ncbi.nlm.nih.gov/gene/5915 , https://www.ncbi.nlm.nih.gov/gene/5916",,,Active,1.0780190508222809,1.8162158401517294,14.387937135814537,1.1579985316187769,0.11871045577184501,0.921813646642518,log2_fold_induction,1.84509804001426,0.593552278859225,,1.3120945709937346,0.6218476269540061,-0.5092731123564529,20,nuclear receptor
ATG_E_Box_CIS_dn,ATG_E_Box_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_009053.1,USF1,upstream transcription factor 1,https://www.ncbi.nlm.nih.gov/gene/7391,,,Active,0.8704127720759011,1.8425805235275676,26.88525102397804,1.4295140957813188,0.09447758303767596,0.725345059903912,log2_fold_induction,1.84509804001426,0.4723879151883798,"[""Borderline active"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.4388126689590537,1.3899924335209446,1.3102337797017762,20,dna binding
ATG_ERa_TRANS_up,"Data from the assay component ATG_ERa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,3.6837029291069,3.333205938244555,2.827490740792482,0.4514011914120584,0.22103062321117403,3.6329798862303213,log2_fold_induction,1.84509804001426,1.10515311605587,,0.059874882295710086,-0.24930864543080872,-0.5639757005177575,20,nuclear receptor
ATG_ERE_CIS_up,"Data from the assay component ATG_ERE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,2.566183048662155,5.0784277314782935,14.72794411229333,1.1681421274942836,0.10106210757931403,2.45845168510378,log2_fold_induction,2.30102999566398,0.5053105378965701,,0.6995772409137563,0.49811762831309625,0.4357427374593096,20,nuclear receptor
ATG_frAR_XSP1_dn,ATG_frAR_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,,ar.L,androgen receptor L homeolog,https://www.ncbi.nlm.nih.gov/gene/399456,,,Active,1.6472281194723561,3.5539276994519438,9.005274143107256,0.9544969383689325,0.15449837088942256,1.3726900996223224,log2_fold_induction,1.30102999566398,0.4634951126682677,,0.7212980438811752,0.7212980438811752,0.4080244445703065,2,nuclear receptor
ATG_frER2_XSP1_up,"The assay endpoint ATG_frER2_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,esr2.L,estrogen receptor 2 L homeolog,https://www.ncbi.nlm.nih.gov/gene/100174814,,,Active,1.7068288269087204,3.7113683423663177,3.1434598478002673,0.49740791736947365,0.15329735284107007,1.7014281547365206,log2_fold_induction,1.30102999566398,0.45989205852321025,,0.3936031730739733,0.3936031730739733,0.268743271625172,2,nuclear receptor
ATG_frER2_XSP2_up,"The assay endpoint ATG_frER2_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,esr2.L,estrogen receptor 2 L homeolog,https://www.ncbi.nlm.nih.gov/gene/100174814,,,Active,1.028150143084161,2.00534045818634,8.687547321850102,0.9388971832456408,0.17090200966241173,0.8567917859495002,log2_fold_induction,1.30102999566398,0.5127060289872352,"[""Only one conc above baseline, active""]",0.9374127817392182,0.9374127817392182,0.32654057470015396,2,nuclear receptor
ATG_GLI_CIS_up,"Data from the assay component ATG_GLI_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_GLI_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GLI1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_005260.1,GLI1,GLI family zinc finger 1,https://www.ncbi.nlm.nih.gov/gene/2735,,,Active,1.01875115857032,2.650041224796601,80.8473607684787,1.9076658470946815,0.07688568381788191,1.0180264116298516,log2_fold_induction,2.30102999566398,0.38442841908940956,,1.8804786616599045,1.8409636045193076,1.7883840588710271,20,dna binding
ATG_hAR_XSP1_dn,ATG_hAR_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,1.6895626332600775,2.82298045862721,7.434951934253013,0.8712781652243267,0.19950104248822853,1.4079688610685035,log2_fold_induction,1.30102999566398,0.5985031274646856,,0.6796972494226735,0.6796972494226735,0.17025338380366706,2,nuclear receptor
ATG_hAR_XSP2_dn,ATG_hAR_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,0.8423134584994307,1.242116491014421,2.338903819381916,0.36901236307869656,0.2260425289127603,0.8638783969329694,log2_fold_induction,1.30102999566398,0.6781275867382809,"[""Only one conc above baseline, active""]",0.7241060605657885,0.7241060605657885,-0.18108326581134704,2,nuclear receptor
ATG_hERa_XSP1_up,"The assay endpoint ATG_hERa_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,,,Active,1.1083667016276693,1.501548657660838,5.06188483416144,0.7043122600523508,0.24604968032456118,1.0134295575900307,log2_fold_induction,1.30102999566398,0.7381490409736835,"[""Only one conc above baseline, active""]",0.8745399870854565,0.8745399870854565,0.16228483588138687,2,nuclear receptor
ATG_hERa_XSP2_up,"The assay endpoint ATG_hERa_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,,,Active,1.971555146211056,3.1535449677931786,5.533141037721476,0.7429717403611842,0.20839564853166204,1.6429626218587332,log2_fold_induction,1.30102999566398,0.6251869455949861,,0.43267297992019255,0.43267297992019255,-0.14580737398177313,2,nuclear receptor
ATG_HIF1a_CIS_up,"Data from the assay component ATG_HIF1a_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HIF1a_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HIF1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.",NP_001521.1,HIF1A,"hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)",https://www.ncbi.nlm.nih.gov/gene/3091,"[122,123,220,150,122,123,220,150]",[801],Active,1.3596476272331905,1.7761886893664145,55.9878774294822,1.748094003159624,0.15309720587379613,1.133039689472454,log2_fold_induction,2.30102999566398,0.7654860293689807,"[""Hit-call potentially confounded by overfitting""]",2.09336240095394,0.83081348690058,-1.2461959851564528,20,dna binding
ATG_IR1_CIS_dn,ATG_IR1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_001193922.1,NR1H4,"nuclear receptor subfamily 1, group H, member 4",https://www.ncbi.nlm.nih.gov/gene/9971,,,Active,0.9545328713023977,1.9485314037996677,28.315608008817218,1.4520258914804458,0.09797459455270192,0.7954440594319359,log2_fold_induction,1.84509804001426,0.4898729727635096,"[""Borderline active"",""Hit-call potentially confounded by overfitting""]",1.4658840003582405,1.2396338680406813,0.8757738527313572,20,nuclear receptor
ATG_Myc_CIS_up,"Data from the assay component ATG_Myc_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Myc_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MYC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.",NP_002458.2,MYC,v-myc avian myelocytomatosis viral oncogene homolog,https://www.ncbi.nlm.nih.gov/gene/4609,,,Active,2.6925426916245954,5.5206122899046255,120.59877120380779,2.0813428827450577,0.09754507472109084,2.2437855765740866,log2_fold_induction,2.30102999566398,0.4877253736054542,,1.875181612849825,1.7937895347922015,1.781085450169974,20,dna binding
ATG_NFI_CIS_up,"Data from the assay component ATG_NFI_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NFI_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFIA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is nuclear factor I.",NP_001128145.1,NFIA,nuclear factor I/A,https://www.ncbi.nlm.nih.gov/gene/4774,,,Active,1.2398390493086278,2.9430312092575295,111.23107658172104,2.0462261406850732,0.08425592262892893,1.228535655236056,log2_fold_induction,2.30102999566398,0.4212796131446447,"[""Only one conc above baseline, active""]",2.010126714928094,1.9721918744192708,1.9268153207708483,20,dna binding
ATG_NRF1_CIS_up,"Data from the assay component ATG_NRF1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NRF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is nuclear respiratory factors.",NP_005002.3,NRF1,nuclear respiratory factor 1,https://www.ncbi.nlm.nih.gov/gene/4899,,,Active,0.8384666559988403,2.0854008545549654,78.10493896023729,1.892678497326182,0.08041299629924369,0.8380128179823265,log2_fold_induction,2.30102999566398,0.40206498149621844,,1.8882296762014377,1.843466378265901,1.773396810113066,20,dna binding
ATG_NRF2_ARE_CIS_up,"Data from the assay component ATG_NRF2_ARE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF2_ARE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFE2L2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_006155.2,NFE2L2,"nuclear factor, erythroid 2-like 2",https://www.ncbi.nlm.nih.gov/gene/4780,"[61,61]",[478],Active,2.47319752037538,3.1846951301401933,50.52556263412478,1.7035111583582516,0.15531769411576343,2.361342491188438,log2_fold_induction,2.30102999566398,0.7765884705788172,,1.5512490569408537,1.4189617372718202,1.2754059994487315,20,dna binding
ATG_Oct_MLP_CIS_up,"Data from the assay component ATG_Oct_MLP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Oct_MLP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene POU2F1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is POU domain protein.",NP_002688.3,POU2F1,POU class 2 homeobox 1,https://www.ncbi.nlm.nih.gov/gene/5451,,,Active,0.9913156605419574,1.46278606590428,90.89177130576822,1.9585245670694826,0.13553802345377633,0.989515005715509,log2_fold_induction,2.30102999566398,0.6776901172688816,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",2.0003557648344596,1.9388038236236445,1.8392336106345744,20,dna binding
ATG_PPARa_TRANS_up,"Data from the assay component ATG_PPARa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_005027.2,PPARA,peroxisome proliferator-activated receptor alpha,https://www.ncbi.nlm.nih.gov/gene/5465,"[51,18,318,6,36,61,58,37,166,37,6,318,51,18,166,36,61,58]",,Active,1.868846151076295,1.6151017312371643,23.995786574823494,1.3801349905471036,0.23142147827985585,1.6181488712111713,log2_fold_induction,2.30102999566398,1.1571073913992793,,1.6407500290642585,1.0981508558330575,0.20180590404082088,20,nuclear receptor
ATG_PPRE_CIS_dn,ATG_PPRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,"NP_005027.2|NP_006229.1|NP_056953.2","PPARA | PPARD | PPARG","peroxisome proliferator-activated receptor alpha , peroxisome proliferator-activated receptor delta , peroxisome proliferator-activated receptor gamma","https://www.ncbi.nlm.nih.gov/gene/5465 , https://www.ncbi.nlm.nih.gov/gene/5467 , https://www.ncbi.nlm.nih.gov/gene/5468",,,Active,0.9950324736764717,1.111289967174373,52.03180012665705,1.7162688512958089,0.1790770191521653,0.9861864246313128,log2_fold_induction,2.30102999566398,0.8953850957608266,"[""Borderline active""]",1.9876411010013513,1.7360435277993598,1.4446978063951774,20,nuclear receptor
ATG_PXRE_CIS_up,"Data from the assay component ATG_PXRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PXRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1,NR1I2,"nuclear receptor subfamily 1, group I, member 2",https://www.ncbi.nlm.nih.gov/gene/8856,"[8,11,60,8,11,60]",,Active,2.2013736209789387,3.303356775581119,3.1433562800033834,0.4973936084023338,0.13328100901796647,2.5782662127064215,log2_fold_induction,1.30102999566398,0.6664050450898323,,0.2916944277835673,0.12628249136296704,-0.04429489311442736,20,nuclear receptor
ATG_PXR_TRANS_up,"Data from the assay component ATG_PXR_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_PXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1,NR1I2,"nuclear receptor subfamily 1, group I, member 2",https://www.ncbi.nlm.nih.gov/gene/8856,"[8,11,60,8,11,60]",,Active,2.41180677357834,1.872450117381872,7.488666942462468,0.8744045158225555,0.2576097222766731,2.0098389779851207,log2_fold_induction,1.84509804001426,1.2880486113833656,,0.9209601443752227,0.6179063735954319,0.12472828088138233,20,nuclear receptor
ATG_RARa_TRANS_dn,ATG_RARa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_000955.1,RARA,"retinoic acid receptor, alpha",https://www.ncbi.nlm.nih.gov/gene/5914,,,Active,2.3570949896649114,2.056796970664386,31.176507272798464,1.4938274592455296,0.22920055049512475,1.9642458250047259,log2_fold_induction,2.30102999566398,1.1460027524756238,,1.4462566964310941,0.7299533731226202,-0.3982564513787259,20,nuclear receptor
ATG_RARb_TRANS_dn,ATG_RARb_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_001277145.1,RARB,"retinoic acid receptor, beta",https://www.ncbi.nlm.nih.gov/gene/5915,,,Active,1.7919387472332569,1.668351961800288,73.22999461372984,1.864689002193283,0.21481543322544586,1.4932822893753008,log2_fold_induction,2.30102999566398,1.0740771661272293,,2.0177888290255286,1.6454757832967644,1.029839134480584,20,nuclear receptor
ATG_RXRb_TRANS_up,"Data from the assay component ATG_RXRb_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_RXRb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_068811.1,RXRB,"retinoid X receptor, beta",https://www.ncbi.nlm.nih.gov/gene/6257,,,Active,2.401413051743088,2.417377663766692,15.045959746343616,1.1774198955820503,0.19867917932204862,2.401901976649932,log2_fold_induction,1.84509804001426,0.9933958966102431,,1.076151617871535,0.8556743769940104,0.5395077419753276,20,nuclear receptor
ATG_Sp1_CIS_up,"Data from the assay component ATG_Sp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Sp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_612482.2,SP1,Sp1 transcription factor,https://www.ncbi.nlm.nih.gov/gene/6667,"[148,148]",,Active,2.5942370577403615,4.937673888592631,86.60457753655503,1.9375408475176608,0.10507931938290839,2.161864214784057,log2_fold_induction,2.30102999566398,0.525396596914542,,1.6240536425922363,1.4850868066618284,1.4349823083191708,20,dna binding
ATG_SREBP_CIS_up,"Data from the assay component ATG_SREBP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_SREBP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SREBF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.",NP_004167.3,SREBF1,sterol regulatory element binding transcription factor 1,https://www.ncbi.nlm.nih.gov/gene/6720,"[62,61,58,34,34,62,61,58]",,Active,0.6136259155020012,1.6888377302509685,103.59786767435136,2.0153508165405545,0.07266842805682862,0.5730421215524555,log2_fold_induction,2.30102999566398,0.3633421402841431,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",2.055571040912546,1.9510483978362756,1.778267055183345,20,dna binding
ATG_trAR_XSP1_dn,ATG_trAR_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/101947425,,,Active,1.0909188663421854,1.9543458134832477,6.469626996296159,0.810879242319388,0.186067184018955,0.9090990552857738,log2_fold_induction,1.30102999566398,0.5582015520568651,"[""Only one conc above baseline, active""]",0.8366599054542154,0.8366599054542154,-0.40133762621334723,2,nuclear receptor
ATG_trERa_XSP1_up,"The assay endpoint ATG_trERa_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/101933533,,,Active,1.2144297260205617,1.5757570092739064,5.589372410575397,0.7473630468980096,0.25689868824385115,1.0120247717027364,log2_fold_induction,1.30102999566398,0.7706960647315535,"[""Only one conc above baseline, active""]",0.9856623847176477,0.9856623847176477,-0.20106301004026994,2,nuclear receptor
ATG_trERa_XSP2_up,"The assay endpoint ATG_trERa_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/101933533,,,Active,2.031559179224113,2.25784706235847,9.632556965284262,0.9837415860354628,0.29992571435167914,1.6929659826908048,log2_fold_induction,1.30102999566398,0.8997771430550374,"[""Only one conc above baseline, active""]",0.9345912865552415,0.9345912865552415,0.5129765348553423,2,nuclear receptor
ATG_Xbp1_CIS_up,"Data from the assay component ATG_Xbp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Xbp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene XBP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_005071.2,XBP1,X-box binding protein 1,https://www.ncbi.nlm.nih.gov/gene/7494,,,Active,1.7915810972360209,3.0416608838770123,97.35976331590933,1.9883795094422276,0.11780281666064009,1.7859495584543321,log2_fold_induction,2.30102999566398,0.5890140833032005,"[""Only one conc above baseline, active""]",1.9496297170988142,1.9121841268663553,1.8690935275229323,20,dna binding
ATG_zfAR_XSP2_dn,ATG_zfAR_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,,ar,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/100005148,,,Active,1.126665747494744,1.3681645674542469,1.1200092966326973,0.049221627544756716,0.2744956696720431,0.9388881229332904,log2_fold_induction,0.845098040014257,0.8234870090161293,"[""Borderline active""]",1.3555637275372456,1.3555637275372456,-2.8233308607587424,2,nuclear receptor
ATG_zfER2a_XSP1_up,"The assay endpoint ATG_zfER2a_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,esr2a,estrogen receptor 2a,https://www.ncbi.nlm.nih.gov/gene/317734,,,Active,1.2853252019923844,1.8624227144867647,9.90576105042791,0.9958878475983614,0.23004537619996163,1.0711043349959568,log2_fold_induction,1.30102999566398,0.6901361285998848,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.0282434358281392,1.0282434358281392,0.5155647726418091,2,nuclear receptor
ATG_zfER2a_XSP2_up,"The assay endpoint ATG_zfER2a_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,esr2a,estrogen receptor 2a,https://www.ncbi.nlm.nih.gov/gene/317734,,,Active,0.7214544229818283,1.2693947050325032,16.367621050314984,1.213985561525571,0.1894484093144628,0.6012120203289706,log2_fold_induction,1.30102999566398,0.5683452279433884,"[""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.2851922254176587,1.2851922254176587,1.094696376013817,2,nuclear receptor
ATG_zfER2b_XSP1_up,"The assay endpoint ATG_zfER2b_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,esr2b,estrogen receptor 2b,https://www.ncbi.nlm.nih.gov/gene/317733,,,Active,4.727660236113196,8.696830290835887,7.026730062342639,0.8467532700753131,0.18120242578858012,3.939716863667723,log2_fold_induction,1.30102999566398,0.5436072773657403,,0.19968751093623038,0.19968751093623038,0.15009372365122764,2,nuclear receptor
ATG_zfER2b_XSP2_up,"The assay endpoint ATG_zfER2b_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,esr2b,estrogen receptor 2b,https://www.ncbi.nlm.nih.gov/gene/317733,,,Active,3.219878071723556,6.188700214539734,8.898004448499904,0.9492926185348036,0.17342780444477252,2.6832317264591663,log2_fold_induction,1.30102999566398,0.5202834133343175,,0.568047287185987,0.568047287185987,0.4405224111715559,2,nuclear receptor
BSK_3C_Eselectin_down,"Data from the assay component BSK_3C_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_000441.2,SELE,selectin E,https://www.ncbi.nlm.nih.gov/gene/6401,,,Active,0.7248949255306918,9.154881511901092,39.99999999999999,1.6020599913279623,0.022749058062569997,0.9041270800000001,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active"",""Noisy data""]",1.6020599913279623,1.6020599913279623,1.0334669168389203,20,cell adhesion molecules
BSK_3C_HLADR_down,"Data from the assay component BSK_3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",NP_061984.2,HLA-DRA,"major histocompatibility complex, class II, DR alpha",https://www.ncbi.nlm.nih.gov/gene/3122,,,Active,0.9139495482890027,11.542500199343834,39.99999999999999,1.6020599913279623,0.025758990402599997,0.95938605,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.0302365576514094,20,cell adhesion molecules
BSK_3C_ICAM1_down,"Data from the assay component BSK_3C_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_ICAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_000192.2,ICAM1,intercellular adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/3383,,,Active,0.945280807676848,11.938190605238693,39.99999999999999,1.6020599913279623,0.016926969131288997,0.62085645,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active"",""Noisy data""]",1.6020599913279623,1.6020599913279623,1.2785811699264384,20,cell adhesion molecules
BSK_3C_IL8_down,"Data from the assay component BSK_3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1,CXCL8,chemokine (C-X-C motif) ligand 8,https://www.ncbi.nlm.nih.gov/gene/3576,,,Active,1.1034820302594877,11.17092090790781,39.99999999999999,1.6020599913279623,0.0329272175904,0.86241518,log10_fold_induction,1.60205999132796,0.0987816527712,"[""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.081362052110326,20,cytokine
BSK_3C_MCP1_down,"Data from the assay component BSK_3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1,CCL2,chemokine (C-C motif) ligand 2,https://www.ncbi.nlm.nih.gov/gene/6347,,,Active,1.0466424429764207,12.34782245646953,39.99999999999999,1.6020599913279623,0.028254440453399997,0.8387611500000001,log10_fold_induction,1.60205999132796,0.08476332136019998,"[""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.2028039602004985,20,cytokine
BSK_3C_MIG_down,"Data from the assay component BSK_3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002407.1,CXCL9,chemokine (C-X-C motif) ligand 9,https://www.ncbi.nlm.nih.gov/gene/4283,,,Active,1.0236062767801184,12.927382781580048,39.99999999999999,1.6020599913279623,0.00716423639925,0.7066711999999999,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Noisy data"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.3788177886935544,20,cytokine
BSK_3C_Proliferation_down,"Data from the assay component BSK_3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.6342826391829242,13.914321082569783,10,1,0.0391510930713,1.3511405,log10_fold_induction,1.60205999132796,0.1174532792139,,1,1,0.9711306765499583,20,cell cycle
BSK_3C_SRB_down,"Data from the assay component BSK_3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.7830276607961905,9.88905454108699,39.99999999999999,1.6020599913279623,0.02172150128694,0.782903525,log10_fold_induction,1.60205999132796,0.07918124604762482,,1.6020599913279623,1.6020599913279623,1.0062087907493618,20,cell cycle
BSK_3C_TissueFactor_down,"Data from the assay component BSK_3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",NP_001984.1,F3,"coagulation factor III (thromboplastin, tissue factor)",https://www.ncbi.nlm.nih.gov/gene/2152,,,Active,0.8599427518558541,6.605257628916551,39.99999999999999,1.6020599913279623,0.04339688170481999,0.65753278,log10_fold_induction,1.60205999132796,0.13019064511446,"[""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.0145960671434606,20,cytokine
BSK_3C_uPAR_down,"Data from the assay component BSK_3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",NP_002650.1,PLAUR,"plasminogen activator, urokinase receptor",https://www.ncbi.nlm.nih.gov/gene/5329,,,Active,0.5613860754717817,4.788242768229628,39.99999999999999,1.6020599913279623,0.0390808697223,0.56080054,log10_fold_induction,1.60205999132796,0.1172426091669,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.1101506961501753,20,cytokine
BSK_3C_VCAM1_down,"Data from the assay component BSK_3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1,VCAM1,vascular cell adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/7412,,,Active,1.4627942396686748,18.473998739409254,10,1,0.0189344513925,1.0792322699999999,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Noisy data""]",1,1,1.0976804814734706,20,cell adhesion molecules
BSK_3C_Vis_down,"Data from the assay component BSK_3C_Vis was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Vis_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, loss-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",, , , ,,,Active,1.1999999999895161,15.1551037636836,39.99999999999999,1.6020599913279623,0,1,log10_fold_induction,1.60205999132796,0.07918124604762482,,1.6020599913279623,1.6020599913279623,1.3920285634245917,20,cell morphology
BSK_4H_Eotaxin3_down,"Data from the assay component BSK_4H_Eotaxin3 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Eotaxin3_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL26. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_006063.1,CCL26,chemokine (C-C motif) ligand 26,https://www.ncbi.nlm.nih.gov/gene/10344,,,Active,0.9630700899718325,11.841433610584726,39.99999999999999,1.6020599913279623,0.027110177186399995,0.9953075,log10_fold_induction,1.60205999132796,0.08133053155919999,"[""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.0442555559942943,20,cytokine
BSK_4H_MCP1_down,"Data from the assay component BSK_4H_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1,CCL2,chemokine (C-C motif) ligand 2,https://www.ncbi.nlm.nih.gov/gene/6347,,,Active,0.38820359986894704,2.4049784214618115,39.99999999999999,1.6020599913279623,0.05380555551,0.30294796,log10_fold_induction,1.60205999132796,0.16141666653,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,0.6775000367070928,20,cytokine
BSK_4H_Pselectin_down,"Data from the assay component BSK_4H_Pselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Pselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELP. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_002996.2,SELP,"selectin P (granule membrane protein 140kDa, antigen CD62)",https://www.ncbi.nlm.nih.gov/gene/6403,,,Active,0.44671940859259973,3.6440068433931074,39.99999999999999,1.6020599913279623,0.04086338910171,0.44658135,log10_fold_induction,1.60205999132796,0.12259016730513,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.0413376261553207,20,cell adhesion molecules
BSK_4H_SRB_down,"Data from the assay component BSK_4H_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_4H_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.9636679196275755,12.17040609651384,39.99999999999999,1.6020599913279623,0.02048812375239,0.79700047,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.397798857804409,20,cell cycle
BSK_4H_uPAR_down,"Data from the assay component BSK_4H_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",NP_002650.1,PLAUR,"plasminogen activator, urokinase receptor",https://www.ncbi.nlm.nih.gov/gene/5329,,,Active,0.6839633296652654,6.18723679524293,39.99999999999999,1.6020599913279623,0.03684807679098,0.531574915,log10_fold_induction,1.60205999132796,0.11054423037293999,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,1.4148926582498165,20,cytokine
BSK_4H_VCAM1_down,"Data from the assay component BSK_4H_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1,VCAM1,vascular cell adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/7412,,,Active,1.317037679934506,16.63320225021911,10,1,0.0228833401839,1.01955847,log10_fold_induction,1.60205999132796,0.07918124604762482,,1,1,0.9826638517600108,20,cell adhesion molecules
BSK_4H_VEGFRII_down,"Data from the assay component BSK_4H_VEGFRII was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VEGFRII_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene KDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",NP_002244.1,KDR,kinase insert domain receptor (a type III receptor tyrosine kinase),https://www.ncbi.nlm.nih.gov/gene/3791,"[43,43]",,Active,0.3785492158161077,3.6175180796185,39.99999999999999,1.6020599913279623,0.03488111715312,0.276466525,log10_fold_induction,1.60205999132796,0.10464335145935999,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,1.2312235456186582,20,kinase
BSK_BE3C_MMP1_up,"Data from the assay component BSK_BE3C_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MMP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",NP_002412.1,MMP1,matrix metallopeptidase 1 (interstitial collagenase),https://www.ncbi.nlm.nih.gov/gene/4312,,,Active,0.1389705734553412,1.5102731491483137,39.99999999999999,1.6020599913279623,0.030672282369078,0.13896906,log10_fold_induction,1.60205999132796,0.092016847107234,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,0.9491493638563611,20,protease
BSK_BE3C_uPA_up,"Data from the assay component BSK_BE3C_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPA_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",NP_002649.1,PLAU,"plasminogen activator, urokinase",https://www.ncbi.nlm.nih.gov/gene/5328,,,Active,0.1796891237285907,2.188575074435602,10,1,0.02736774958092,0.18495156499999998,log10_fold_induction,1.60205999132796,0.08210324874276,"[""Less than 50% efficacy""]",1,1,0.37237422967165634,20,protease
BSK_CASM3C_HLADR_down,"Data from the assay component BSK_CASM3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",NP_061984.2,HLA-DRA,"major histocompatibility complex, class II, DR alpha",https://www.ncbi.nlm.nih.gov/gene/3122,,,Active,0.3518296079841826,3.3436518179978463,39.99999999999999,1.6020599913279623,0.03507438644283,0.274994385,log10_fold_induction,1.60205999132796,0.10522315932849,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,0.6668598868726237,20,cell adhesion molecules
BSK_CASM3C_Proliferation_down,"Data from the assay component BSK_CASM3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_CASM3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.5104733312362546,5.249287554412894,39.99999999999999,1.6020599913279623,0.032415404055299996,0.40742499,log10_fold_induction,1.60205999132796,0.09724621216589999,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.0792644198574886,20,cell cycle
BSK_CASM3C_Thrombomodulin_up,"Data from the assay component BSK_CASM3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_Thrombomodulin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000352.1,THBD,thrombomodulin,https://www.ncbi.nlm.nih.gov/gene/7056,,,Active,0.20657699094303067,2.0599081443600293,39.99999999999999,1.6020599913279623,0.0334281881304,0.206313435,log10_fold_induction,1.60205999132796,0.10028456439120001,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,0.8797871443368637,20,gpcr
BSK_hDFCGF_CollagenIII_down,"Data from the assay component BSK_hDFCGF_CollagenIII was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_CollagenIII_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene COL3A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""collagen"".",NP_000081.1,COL3A1,"collagen, type III, alpha 1",https://www.ncbi.nlm.nih.gov/gene/1281,,,Active,0.5524735833847598,3.9032042565934755,40.000000000000014,1.6020599913279625,0.047181200117099996,0.54262516,log10_fold_induction,1.60205999132796,0.14154360035129998,"[""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.8799385298314744,20,cell adhesion molecules
BSK_hDFCGF_IL8_down,"Data from the assay component BSK_hDFCGF_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1,CXCL8,chemokine (C-X-C motif) ligand 8,https://www.ncbi.nlm.nih.gov/gene/3576,,,Active,1.1753887348611216,14.844281866367263,40.000000000000014,1.6020599913279625,0.008495260327134,1.1733495999999999,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Noisy data""]",1.6020599913279625,1.6020599913279625,1.0249791379124904,20,cytokine
BSK_hDFCGF_IP10_down,"Data from the assay component BSK_hDFCGF_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2,CXCL10,chemokine (C-X-C motif) ligand 10,https://www.ncbi.nlm.nih.gov/gene/3627,,,Active,1.3078514047983614,16.169075316070874,10,1,0.0269619913164,1.26933085,log10_fold_induction,1.60205999132796,0.0808859739492,"[""Noisy data""]",1,1,0.932730080052627,20,cytokine
BSK_hDFCGF_MCSF_down,"Data from the assay component BSK_hDFCGF_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",NP_000748.3,CSF1,colony stimulating factor 1 (macrophage),https://www.ncbi.nlm.nih.gov/gene/1435,,,Active,1.0230547900392084,9.567695333428192,10,1,0.0356426758443,0.82440287,log10_fold_induction,1.60205999132796,0.10692802753289998,"[""Noisy data""]",1,1,0.7527324594053634,20,cytokine
BSK_hDFCGF_MIG_down,"Data from the assay component BSK_hDFCGF_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002407.1,CXCL9,chemokine (C-X-C motif) ligand 9,https://www.ncbi.nlm.nih.gov/gene/4283,,,Active,1.4729057994941295,18.601700188049918,10,1,0.015977820005069997,1.2071661,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Noisy data""]",1,1,0.998234959434546,20,cytokine
BSK_hDFCGF_MMP1_down,"Data from the assay component BSK_hDFCGF_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",NP_002412.1,MMP1,matrix metallopeptidase 1 (interstitial collagenase),https://www.ncbi.nlm.nih.gov/gene/4312,,,Active,0.8785683371997598,11.051426488339148,40.000000000000014,1.6020599913279625,0.026499394689809996,0.70575568,log10_fold_induction,1.60205999132796,0.07949818406942999,"[""Noisy data""]",1.6020599913279625,1.6020599913279625,1.40629761769661,20,protease
BSK_hDFCGF_PAI1_down,"Data from the assay component BSK_hDFCGF_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_PAI1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator inhibitor"".",NP_000593.1,SERPINE1,"serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1",https://www.ncbi.nlm.nih.gov/gene/5054,,,Active,0.9987886987630612,6.029955672328439,10,1,0.055212605920499994,0.937904925,log10_fold_induction,1.60205999132796,0.1656378177615,"[""Noisy data""]",1,1,0.5838184711796097,20,cytokine
BSK_hDFCGF_Proliferation_down,"Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.5262255179572422,11.263359261019259,4,0.6020599913279624,0.0451678604517,1.33914025,log10_fold_induction,1.60205999132796,0.1355035813551,"[""Noisy data""]",0.6020599913279624,0.6020599913279624,0.5608281073311622,20,cell cycle
BSK_hDFCGF_SRB_down,"Data from the assay component BSK_hDFCGF_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.8256012303489961,10.426726927894329,10,1,0.024374730148650003,0.805644365,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Noisy data""]",1,1,0.7902789432839299,20,cell cycle
BSK_hDFCGF_TIMP1_down,"Data from the assay component BSK_hDFCGF_TIMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_TIMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease inhibitor"" intended target family, where the subfamily is ""metalloproteinase inhibitor"".",NP_003245.1,TIMP1,TIMP metallopeptidase inhibitor 1,https://www.ncbi.nlm.nih.gov/gene/7076,,,Active,0.6074621292411437,4.527134077804246,40.000000000000014,1.6020599913279625,0.0447274971171,0.6072703500000001,log10_fold_induction,1.60205999132796,0.1341824913513,"[""Noisy data""]",1.6020599913279625,1.6020599913279625,1.0454649114545242,20,protease inhibitor
BSK_hDFCGF_VCAM1_down,"Data from the assay component BSK_hDFCGF_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1,VCAM1,vascular cell adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/7412,,,Active,0.8765780022912146,6.203689070949048,10,1,0.04709982465089999,0.87654298,log10_fold_induction,1.60205999132796,0.14129947395269998,"[""Noisy data""]",1,1,0.9142394526047322,20,cell adhesion molecules
BSK_KF3CT_ICAM1_down,"Data from the assay component BSK_KF3CT_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_ICAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_000192.2,ICAM1,intercellular adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/3383,,,Active,0.5795170423905796,7.318867425274159,40.000000000000014,1.6020599913279625,0.02073805097175,0.345305705,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Noisy data"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,1.1937199893615522,20,cell adhesion molecules
BSK_KF3CT_IL1a_down,"Data from the assay component BSK_KF3CT_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000566.3,IL1A,"interleukin 1, alpha",https://www.ncbi.nlm.nih.gov/gene/3552,,,Active,0.39945519595489226,4.65324546784774,40.000000000000014,1.6020599913279625,0.0286148093637,0.31562789999999996,log10_fold_induction,1.60205999132796,0.08584442809109999,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.9781111267270326,20,cytokine
BSK_KF3CT_IP10_down,"Data from the assay component BSK_KF3CT_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2,CXCL10,chemokine (C-X-C motif) ligand 10,https://www.ncbi.nlm.nih.gov/gene/3627,,,Active,1.2092959196129,15.272504285743999,40.000000000000014,1.6020599913279625,0.0138351257877,0.93880265,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Noisy data""]",1.6020599913279625,1.6020599913279625,0.9595111134230547,20,cytokine
BSK_KF3CT_MCP1_down,"Data from the assay component BSK_KF3CT_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1,CCL2,chemokine (C-C motif) ligand 2,https://www.ncbi.nlm.nih.gov/gene/6347,,,Active,0.778608651199034,6.776147596093688,40.000000000000014,1.6020599913279625,0.0383014409568,0.5089128949999999,log10_fold_induction,1.60205999132796,0.1149043228704,"[""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.82635070035047,20,cytokine
BSK_KF3CT_MMP9_down,"Data from the assay component BSK_KF3CT_MMP9 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MMP9_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",AAM97934.1,MMP9,"matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)",https://www.ncbi.nlm.nih.gov/gene/4318,,,Active,0.8511424595369005,10.16856519540334,10,1,0.027901099882530003,0.8341143799999999,log10_fold_induction,1.60205999132796,0.08370329964759,"[""Noisy data""]",1,1,0.6194157643586786,20,protease
BSK_KF3CT_SRB_down,"Data from the assay component BSK_KF3CT_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_KF3CT_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.42620064079262415,5.382595779514243,40.000000000000014,1.6020599913279625,0.00501083847705,0.49170501499999997,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.9706263726555489,20,cell cycle
BSK_KF3CT_TGFb1_down,"Data from the assay component BSK_KF3CT_TGFb1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TGFb1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""growth factor"" intended target family, where the subfamily is ""transforming growth factor beta"".",P01137.2,TGFB1,"transforming growth factor, beta 1",https://www.ncbi.nlm.nih.gov/gene/7040,,,Active,0.5240353819506385,4.9084196285931725,39.99999999999999,1.6020599913279623,0.0355875157113,0.38496165,log10_fold_induction,1.60205999132796,0.10676254713389999,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,1.1469974032605275,20,growth factor
BSK_KF3CT_TIMP2_down,"Data from the assay component BSK_KF3CT_TIMP2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TIMP2_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease inhibitor"" intended target family, where the subfamily is ""metalloproteinase inhibitor"".",,TIMP2,TIMP metallopeptidase inhibitor 2,https://www.ncbi.nlm.nih.gov/gene/7077,,,Active,0.8196609771543648,8.916001676825502,40.000000000000014,1.6020599913279625,0.030643817220029995,0.679302155,log10_fold_induction,1.60205999132796,0.09193145166008998,,1.6020599913279625,1.6020599913279625,0.9366750171672285,20,protease inhibitor
BSK_KF3CT_uPA_down,"Data from the assay component BSK_KF3CT_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_uPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",NP_002649.1,PLAU,"plasminogen activator, urokinase",https://www.ncbi.nlm.nih.gov/gene/5328,,,Active,0.533492742140623,6.737614886986564,40.000000000000014,1.6020599913279625,0.020151273081261,0.3390035,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,1.4931160847765659,20,protease
BSK_LPS_CD40_down,"Data from the assay component BSK_LPS_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001241.1,CD40,"CD40 molecule, TNF receptor superfamily member 5",https://www.ncbi.nlm.nih.gov/gene/958,,,Active,0.4682323217336094,3.392283497042217,40.000000000000014,1.6020599913279625,0.0460095510042,0.46808278000000003,log10_fold_induction,1.60205999132796,0.13802865301259998,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,1.0457191300613815,20,cytokine
BSK_LPS_Eselectin_down,"Data from the assay component BSK_LPS_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_000441.2,SELE,selectin E,https://www.ncbi.nlm.nih.gov/gene/6401,,,Active,0.9988331522147731,12.614516720461927,40.000000000000014,1.6020599913279625,0.0245760564798,0.7947844500000001,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.4007862220972798,20,cell adhesion molecules
BSK_LPS_IL1a_down,"Data from the assay component BSK_LPS_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000566.3,IL1A,"interleukin 1, alpha",https://www.ncbi.nlm.nih.gov/gene/3552,,,Active,0.5227339194194112,4.235653776783866,40.000000000000014,1.6020599913279625,0.041137602124499996,0.371160685,log10_fold_induction,1.60205999132796,0.1234128063735,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,0.941208675599346,20,cytokine
BSK_LPS_IL8_down,"Data from the assay component BSK_LPS_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1,CXCL8,chemokine (C-X-C motif) ligand 8,https://www.ncbi.nlm.nih.gov/gene/3576,,,Active,0.9245068799944085,10.416233214233479,40.000000000000014,1.6020599913279625,0.029585451252860995,0.736803,log10_fold_induction,1.60205999132796,0.08875635375858298,"[""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.0854713636326991,20,cytokine
BSK_LPS_MCP1_down,"Data from the assay component BSK_LPS_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1,CCL2,chemokine (C-C motif) ligand 2,https://www.ncbi.nlm.nih.gov/gene/6347,,,Active,0.8290442096674593,9.24517998775611,40.000000000000014,1.6020599913279625,0.029891042711459998,0.79711858,log10_fold_induction,1.60205999132796,0.08967312813438,"[""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.2585575379350722,20,cytokine
BSK_LPS_MCSF_down,"Data from the assay component BSK_LPS_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",NP_000748.3,CSF1,colony stimulating factor 1 (macrophage),https://www.ncbi.nlm.nih.gov/gene/1435,,,Active,0.41734596756715125,4.0046997580758825,40.000000000000014,1.6020599913279625,0.0347380155633,0.41681255500000003,log10_fold_induction,1.60205999132796,0.1042140466899,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,1.1210040784782567,20,cytokine
BSK_LPS_PGE2_down,"Data from the assay component BSK_LPS_PGE2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_PGE2_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PTGER2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000947.2,PTGER2,"prostaglandin E receptor 2 (subtype EP2), 53kDa",https://www.ncbi.nlm.nih.gov/gene/5732,,,Active,0.45966693599334174,3.260756370734342,4,0.6020599913279624,0.04698980683529999,0.36969724000000004,log10_fold_induction,1.60205999132796,0.14096942050589997,"[""Less than 50% efficacy""]",0.6020599913279624,0.6020599913279624,-0.4755366540821855,20,gpcr
BSK_LPS_SRB_down,"Data from the assay component BSK_LPS_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_LPS_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.6844851845515446,8.644536663894506,40.000000000000014,1.6020599913279625,0.018219059086199998,0.5461137,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,1.2214686527143848,20,cell cycle
BSK_LPS_TissueFactor_down,"Data from the assay component BSK_LPS_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",NP_001984.1,F3,"coagulation factor III (thromboplastin, tissue factor)",https://www.ncbi.nlm.nih.gov/gene/2152,,,Active,0.5577567224848796,4.601759064371128,40.000000000000014,1.6020599913279625,0.0404017039776,0.433970705,log10_fold_induction,1.60205999132796,0.1212051119328,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.4146900685361954,20,cytokine
BSK_LPS_TNFa_down,"Data from the assay component BSK_LPS_TNFa was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TNFa_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TNF. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_000585.2,TNF,tumor necrosis factor,https://www.ncbi.nlm.nih.gov/gene/7124,,,Active,1.825555199672053,13.407260576050101,40.000000000000014,1.6020599913279625,0.04538722854225,1.48677945,log10_fold_induction,1.60205999132796,0.13616168562675,"[""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.0620363622673579,20,cytokine
BSK_LPS_VCAM1_down,"Data from the assay component BSK_LPS_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1,VCAM1,vascular cell adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/7412,,,Active,0.7889367559952565,9.96368200016375,40.000000000000014,1.6020599913279625,0.0224178208338,0.57098558,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.0733323674416186,20,cell adhesion molecules
BSK_SAg_CD38_down,"Data from the assay component BSK_SAg_CD38 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD38_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD38. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""other cytokine"".",NP_001766.2,CD38,CD38 molecule,https://www.ncbi.nlm.nih.gov/gene/952,,,Active,0.8076326395529783,10.199797046224996,40.000000000000014,1.6020599913279625,0.0243080164845,0.6518107,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.12653977787918,20,cytokine
BSK_SAg_CD40_down,"Data from the assay component BSK_SAg_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001241.1,CD40,"CD40 molecule, TNF receptor superfamily member 5",https://www.ncbi.nlm.nih.gov/gene/958,,,Active,0.8117704796571079,8.142250601881639,40.000000000000014,1.6020599913279625,0.0332328459435,0.6516134499999999,log10_fold_induction,1.60205999132796,0.09969853783049999,"[""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.0953909745003696,20,cytokine
BSK_SAg_CD69_down,"Data from the assay component BSK_SAg_CD69 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD69_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD69. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001772.1,CD69,CD69 molecule,https://www.ncbi.nlm.nih.gov/gene/969,,,Active,0.4685947108904462,4.425754283165459,40.000000000000014,1.6020599913279625,0.03529302057225,0.467684345,log10_fold_induction,1.60205999132796,0.10587906171674999,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.1440349350697736,20,cytokine
BSK_SAg_Eselectin_down,"Data from the assay component BSK_SAg_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_000441.2,SELE,selectin E,https://www.ncbi.nlm.nih.gov/gene/6401,,,Active,0.881091113926302,7.677921383995097,40.000000000000014,1.6020599913279625,0.038252154885,0.71716545,log10_fold_induction,1.60205999132796,0.114756464655,"[""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.4026489311447499,20,cell adhesion molecules
BSK_SAg_IL8_down,"Data from the assay component BSK_SAg_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1,CXCL8,chemokine (C-X-C motif) ligand 8,https://www.ncbi.nlm.nih.gov/gene/3576,,,Active,0.5700090316025939,3.7946056897215334,40.000000000000014,1.6020599913279625,0.050071872038999994,0.45649696500000003,log10_fold_induction,1.60205999132796,0.150215616117,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.1992759932911967,20,cytokine
BSK_SAg_MCP1_down,"Data from the assay component BSK_SAg_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1,CCL2,chemokine (C-C motif) ligand 2,https://www.ncbi.nlm.nih.gov/gene/6347,,,Active,0.9539133561050162,10.020597626971728,40.000000000000014,1.6020599913279625,0.031731751991099996,0.74951425,log10_fold_induction,1.60205999132796,0.09519525597329999,"[""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.411840040540291,20,cytokine
BSK_SAg_MIG_down,"Data from the assay component BSK_SAg_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002407.1,CXCL9,chemokine (C-X-C motif) ligand 9,https://www.ncbi.nlm.nih.gov/gene/4283,,,Active,1.2880143690196664,16.266659509815867,40.000000000000014,1.6020599913279625,0.00921114872622,1.178863,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.3701303328612662,20,cytokine
BSK_SAg_PBMCCytotoxicity_down,"Data from the assay component BSK_SAg_PBMCCytotoxicity was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_PBMCCytotoxicity_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",, , , ,,,Active,0.5559432342722737,7.021147835156481,10,1,0.0217234984974,0.555908355,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy""]",1,1,0.9588804762668889,20,cell cycle
BSK_SAg_Proliferation_down,"Data from the assay component BSK_SAg_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.0572062110947993,8.833626496722603,10,1,0.0398932500141,1.05082895,log10_fold_induction,1.60205999132796,0.1196797500423,,1,1,0.9043338494918509,20,cell cycle
BSK_SAg_SRB_down,"Data from the assay component BSK_SAg_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.6406935040731958,8.091480445860128,40.000000000000014,1.6020599913279625,0.017346765986949,0.6571032400000001,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.0647351344535618,20,cell cycle
CCTE_Padilla_ZF_144hpf_TERATOSCORE_up,"Data from the assay component CCTE_Padilla_ZF_144hpf_TERATOSCORE was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Padilla_ZF_144hpf_TERATOSCORE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defect  as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""malformation"" intended target family, where the subfamily is ""total"".",, , , ,,,Active,96.1208457063577,4.806042285317885,8.190792346640954,0.913325915817725,1.53481347591287,97.1931948371379,percent_activity,1.90308998699194,20,"[""Noisy data"",""Noisy data""]",0.731105279848023,0.505760310639858,0.61377280222204,20,malformation
CCTE_Shafer_MEA_acute_burst_percentage_mean_dn,"Data from the assay component CCTE_Shafer_MEA_acute_burst_percentage_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_burst_percentage_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,36.21848617918684,2.474680635091659,31.35181949964917,1.4962627501341186,4.878540105417866,23.71888093443847,percent_activity,1.60205999132796,14.635620316253597,"[""Only one conc above baseline, active""]",1.4467392357146398,1.4467392357146398,1.2161322860338946,20,neuroactivity
CCTE_Shafer_MEA_acute_synchrony_index_dn,"Data from the assay component CCTE_Shafer_MEA_acute_synchrony_index was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_synchrony_index_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,17.963180976857018,1.7373174492496586,37.1025056914997,1.5694032403763711,3.446535919426672,11.980711995461785,percent_activity,1.60205999132796,10.339607758280016,"[""Borderline active"",""Only one conc above baseline, active""]",1.5862117150891344,1.5862117150891344,1.4482101318750151,20,neuroactivity
CCTE_Shafer_MEA_dev_AB_dn,"Data from the assay component CCTE_Shafer_MEA_dev_AB was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_AB_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cell viability.",, , , ,,,Active,99.4647040904187,5.099293755085889,4.749629561676668,0.676659738973649,6.50186142549743,99.5695244480121,percent_activity,1,19.5055842764923,,0.600071105015502,0.600071105015502,0.557379419312628,20,cell cycle
CCTE_Shafer_MEA_dev_active_electrodes_number_dn,"Data from the assay component CCTE_Shafer_MEA_dev_active_electrodes_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_active_electrodes_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.834770385303,3.8086787680945418,4.040102865511526,0.606392422871819,8.825,100,percent_activity,1,26.475,,0.507475042512772,0.507475042512772,0.395933708614756,20,neurodevelopment
CCTE_Shafer_MEA_dev_burst_duration_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_burst_duration_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_burst_duration_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.276203229269,1.4003086982803212,6.347400393745915,0.802595894455421,24.1080659223316,100,percent_activity,1,72.3241977669948,,0.852296516636945,0.852296516636945,0.683315579451044,20,neurodevelopment
CCTE_Shafer_MEA_dev_bursting_electrodes_number_dn,"Data from the assay component CCTE_Shafer_MEA_dev_bursting_electrodes_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_bursting_electrodes_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.191986125536,2.61303799419088,4.031050450162876,0.605418233551275,12.7810344827586,100,percent_activity,1,38.3431034482758,,0.571561653301572,0.571561653301572,0.449828400949703,20,neurodevelopment
CCTE_Shafer_MEA_dev_burst_rate_dn,"Data from the assay component CCTE_Shafer_MEA_dev_burst_rate was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_burst_rate_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.909603536477,1.3776564126970186,4.114136152566569,0.614278660068944,24.4157644839102,100,percent_activity,1,73.2472934517306,,0.707673240842923,0.707673240842923,0.403542272848511,20,neurodevelopment
CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_correlation_coefficient_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,102.006758551372,2.0002260259298206,4.080716672198257,0.610736442366404,16.9992052946372,100,percent_activity,1,50.9976158839116,,0.610709262370596,0.610709262370596,0.346486655662369,20,neurodevelopment
CCTE_Shafer_MEA_dev_firing_rate_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_firing_rate_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_firing_rate_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.937126003446,1.4281163102198677,4.055766265958565,0.608072918630662,23.5595017205814,100,percent_activity,1,70.6785051617442,,0.691317372436399,0.691317372436399,0.392472606731686,20,neurodevelopment
CCTE_Shafer_MEA_dev_interburst_interval_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_interburst_interval_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_interburst_interval_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.414220430397,1.5687145727224578,6.43648842109324,0.808648992315948,21.5493249895668,100,percent_activity,1,64.6479749687004,,0.839287197887531,0.839287197887531,0.689368677996513,20,neurodevelopment
CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.004225021548,1.1739150548090818,2.9727265224365986,0.473154957889873,28.3962127730534,100,percent_activity,1,85.1886383191602,"[""Borderline active""]",0.568113408244224,0.568113408244224,0.353873893541293,20,neurodevelopment
CCTE_Shafer_MEA_dev_LDH_dn,"Data from the assay component CCTE_Shafer_MEA_dev_LDH was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_LDH_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cell viability.",, , , ,,,Active,100.333811677941,4.198972225348375,4.336837166843597,0.637173116207125,7.96495001580351,99.9631938533735,percent_activity,1.30102999566398,23.8948500474105,,0.532809339499035,0.532809339499035,0.439972546683203,20,cell cycle
CCTE_Shafer_MEA_dev_mutual_information_norm_dn,"Data from the assay component CCTE_Shafer_MEA_dev_mutual_information_norm was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_mutual_information_norm_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999999668378,1.6582294960116233,1.9634413465127305,0.293017932208762,24.1221133658926,100,percent_activity,1,72.3663400976778,,0.548932621469391,0.548932621469391,-1.05155369104771,20,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_duration_std_dn,"Data from the assay component CCTE_Shafer_MEA_dev_network_spike_duration_std was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_duration_std_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999999950855,1.566984021750349,3.129867324598205,0.495525928148324,25.5267440053011,100,percent_activity,1,76.5802320159033,,0.765246672903017,0.765246672903017,-0.548908016266135,20,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_number_dn,"Data from the assay component CCTE_Shafer_MEA_dev_network_spike_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,109.79658815357,1.4026274852805145,1.26210016984764,0.101093825182018,26.0930739643514,100,percent_activity,1,78.2792218930542,,0.548457122024033,0.548457122024033,-0.9793839493453,20,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_peak_dn,"Data from the assay component CCTE_Shafer_MEA_dev_network_spike_peak was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_peak_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.588928008432,3.711013242801003,3.869086112766879,0.587608395754663,9.03517192629845,100,percent_activity,1,27.1055157788953,,0.495401312612779,0.495401312612779,0.384464800422852,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_burst_interspike_interval_dn,"Data from the assay component CCTE_Shafer_MEA_dev_per_burst_interspike_interval was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_per_burst_interspike_interval_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.311806624454,1.461102726000951,6.374243633216596,0.80442865884582,23.1130923289574,100,percent_activity,1,69.3392769868722,,0.846453948301657,0.846453948301657,0.68514834325483,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn,"Data from the assay component CCTE_Shafer_MEA_dev_per_burst_spike_percent was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.08752068095,2.950946225394742,4.27167848171947,0.630598557019127,11.305698018671,100,percent_activity,1,33.917094056013,,0.5916981586061,0.5916981586061,0.502705309707097,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.020977351895,1.833960950030602,3.767231851006083,0.576022349301758,18.1794087728033,100,percent_activity,1,54.5382263184099,,0.585882321377273,0.585882321377273,0.456703474686591,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn,"Data from the assay component CCTE_Shafer_MEA_dev_per_network_spike_spike_percent was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.096685066444,1.7985581076395465,4.578475308404731,0.660720876390555,18.5512836905804,100,percent_activity,1,55.6538510717412,,0.672932588683227,0.672932588683227,0.541440292013427,20,neurodevelopment
CCTE_Shafer_MEA_dev_spike_duration_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_spike_duration_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_spike_duration_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999999997061,2.821843090578774,3.3710513736414875,0.527765371067102,14.1751326048452,100,percent_activity,1,42.5253978145356,,0.254679985867349,0.254679985867349,-0.472536778927279,20,neurodevelopment
LTEA_HepaRG_ABCB1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000918.2,ABCB1,"ATP-binding cassette, sub-family B (MDR/TAP), member 1",https://www.ncbi.nlm.nih.gov/gene/5243,,,Active,0.688026607355642,1.8134829213979424,35.247469167917224,1.54712793931701,0.126465046759354,0.53915771932161,log2_fold_induction,2,0.379395140278062,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.65015363716744,1.65015363716744,0.450532408536341,20,transporter
LTEA_HepaRG_ABCC2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000383.1,ABCC2,"ATP-binding cassette, sub-family C (CFTR/MRP), member 2",https://www.ncbi.nlm.nih.gov/gene/1244,,,Active,0.642009997841929,1.4959527606442453,9.550424671197831,0.980022683443147,0.143054873284778,0.65163780062057,log2_fold_induction,2,0.429164619854334,,1.12720381237632,1.12720381237632,0.518876657339489,20,transporter
LTEA_HepaRG_ABCG2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_004818.2,ABCG2,"ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)",https://www.ncbi.nlm.nih.gov/gene/9429,,,Active,0.750638479211325,1.2455933796336476,8.603604968743491,0.934680461706897,0.200878417062049,0.77209420310167,log2_fold_induction,1.47712125471966,0.602635251186147,,1.05795096764083,1.05795096764083,0.741775952283016,20,transporter
LTEA_HepaRG_APOA5_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_443200.2,APOA5,apolipoprotein A-V,https://www.ncbi.nlm.nih.gov/gene/116519,,,Active,1.33223499202005,1.5575825046006115,83.9887095195687,1.92422090840816,0.285107420866427,1.06821201326993,log2_fold_induction,2,0.855322262599281,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.95593226859073,1.95593226859073,1.80494058541744,20,apolipoprotein
LTEA_HepaRG_BID_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001187.1,BID,BH3 interacting domain death agonist,https://www.ncbi.nlm.nih.gov/gene/637,,,Active,1.01127389539415,1.448932587309957,0.051384640255326824,-1.2891666796281,0.232648020630518,1.09675945417172,log2_fold_induction,0,0.697944061891554,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",-1.2456893180913,-1.2456893180913,-1.40844700139902,20,cell cycle
LTEA_HepaRG_CYP1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000490.1,CYP1A1,"cytochrome P450, family 1, subfamily A, polypeptide 1",https://www.ncbi.nlm.nih.gov/gene/1543,"[57,57]",,Active,3.29853919536623,3.6626803318744945,40.1050351729659,1.60319890156173,0.300193564683644,2.73799373574671,log2_fold_induction,2,0.900580694050932,,1.33867767301217,1.33867767301217,1.00972110507005,20,cyp
LTEA_HepaRG_CYP2B6_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000758.1,CYP2B6,"cytochrome P450, family 2, subfamily B, polypeptide 6",https://www.ncbi.nlm.nih.gov/gene/1555,,,Active,3.58950737688965,4.761528696783363,1.6354634220035034,0.21364083534594,0.251285361310856,3.66518767533658,log2_fold_induction,1.47712125471966,0.753856083932568,,-0.0873311217605383,-0.0873311217605383,-0.285521514458823,20,cyp
LTEA_HepaRG_CYP2C19_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000760.1,CYP2C19,"cytochrome P450, family 2, subfamily C, polypeptide 19",https://www.ncbi.nlm.nih.gov/gene/1557,,,Active,1.36010921673047,2.4252514732641446,6.93989236292792,0.841352734640883,0.186937207917646,1.32064946467567,log2_fold_induction,2,0.560811623752938,,0.736760511733597,0.736760511733597,0.192802644725663,20,cyp
LTEA_HepaRG_CYP2C8_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000761.3,CYP2C8,"cytochrome P450, family 2, subfamily C, polypeptide 8",https://www.ncbi.nlm.nih.gov/gene/1558,,,Active,1.20100000716168,1.8551158105993004,4.799408751269001,0.681187739067872,0.215799646271804,0.98854215345037,log2_fold_induction,1.47712125471966,0.647398938815412,,0.72484845439263,0.72484845439263,0.0682731152844414,20,cyp
LTEA_HepaRG_CYP2C9_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000762.2,CYP2C9,"cytochrome P450, family 2, subfamily C, polypeptide 9",https://www.ncbi.nlm.nih.gov/gene/1559,,,Active,1.40309670009523,1.48996849106929,5.138127577487736,0.710804883408544,0.313898517206961,1.06937414785158,log2_fold_induction,1.47712125471966,0.941695551620883,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",0.988067084246237,0.988067084246237,-0.143127274471788,20,cyp
LTEA_HepaRG_CYP2E1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000764.1,CYP2E1,"cytochrome P450, family 2, subfamily E, polypeptide 1",https://www.ncbi.nlm.nih.gov/gene/1571,,,Active,2.06129958950102,4.303991042728533,46.647868150441944,1.66883180088734,0.159642493756543,1.7144469993866,log2_fold_induction,2,0.478927481269629,,1.40559212969951,1.40559212969951,1.18487095870761,20,cyp
LTEA_HepaRG_CYP3A4_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_059488.2,CYP3A4,"cytochrome P450, family 3, subfamily A, polypeptide 4",https://www.ncbi.nlm.nih.gov/gene/1576,,,Active,2.81414166847063,2.3716390415379394,7.395851647827444,0.868988191132877,0.395526977922934,2.88486674807583,log2_fold_induction,2,1.1865809337688,,0.809956071714262,0.809956071714262,0.458531879458806,20,cyp
LTEA_HepaRG_CYP3A5_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000768.1,CYP3A5,"cytochrome P450, family 3, subfamily A, polypeptide 5",https://www.ncbi.nlm.nih.gov/gene/1577,,,Active,1.0046006163194,1.31401091109259,18.383053613888503,1.26441765381345,0.254843296413747,0.940037975837904,log2_fold_induction,2,0.764529889241241,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.58172677654294,1.58172677654294,0.6625158807798,20,cyp
LTEA_HepaRG_CYP3A7_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000756.3,CYP3A7,"cytochrome P450, family 3, subfamily A, polypeptide 7",https://www.ncbi.nlm.nih.gov/gene/1551,,,Active,1.87563495147997,2.4167830357037894,5.363442418238722,0.729443622410572,0.258695812266514,1.8897746256744,log2_fold_induction,2,0.776087436799542,,0.662924973109709,0.662924973109709,0.309922682189252,20,cyp
LTEA_HepaRG_FABP1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001434.1,FABP1,"fatty acid binding protein 1, liver",https://www.ncbi.nlm.nih.gov/gene/2168,,,Active,1.14760424799127,2.377990758676677,37.84304398597234,1.57798606253792,0.160864691309103,1.09227798123346,log2_fold_induction,2,0.482594073927309,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.53261682996428,1.53261682996428,1.26707475806842,20,transporter
LTEA_HepaRG_FASN_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_004095.4,FASN,fatty acid synthase,https://www.ncbi.nlm.nih.gov/gene/2194,"[58,34,34,58]",,Active,0.946040504708238,2.5740099167818205,44.785817397606735,1.65114050504441,0.122511895873739,0.807930384560136,log2_fold_induction,2,0.367535687621217,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.56153710227042,1.56153710227042,1.21712966057483,20,lyase
LTEA_HepaRG_GADD45A_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001915.1,GADD45A,"growth arrest and DNA-damage-inducible, alpha",https://www.ncbi.nlm.nih.gov/gene/1647,,,Active,1.06922496279009,1.765603362123508,0.069259347626399,-1.15952160351121,0.201862053831487,1.09153986760463,log2_fold_induction,0,0.605586161494461,"[""Hit-call potentially confounded by overfitting"",""Hit-call potentially confounded by overfitting""]",-1.14502201666939,-1.14502201666939,-1.27880245880161,20,cell cycle
LTEA_HepaRG_GADD45B_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_056490.2,GADD45B,"growth arrest and DNA-damage-inducible, beta",https://www.ncbi.nlm.nih.gov/gene/4616,,,Active,0.611670215151245,1.4579856887584373,86.70319312838117,1.93803509208405,0.139843671504558,0.463691606932415,log2_fold_induction,2,0.419531014513674,"[""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.98042860704327,1.98042860704327,1.81875476892342,20,mutagenicity response
LTEA_HepaRG_HSPA1A_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_005337.2,HSPA1A,heat shock 70kDa protein 1A,https://www.ncbi.nlm.nih.gov/gene/3303,,,Active,0.730636015183677,1.5412424536773288,38.41696632394139,1.58452306690801,0.158018835916096,0.586193530962639,log2_fold_induction,2,0.474056507748288,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.82674216694908,1.82674216694908,0.717573705046077,20,dna binding
LTEA_HepaRG_IGF1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,,IGF1,insulin-like growth factor 1 (somatomedin C),https://www.ncbi.nlm.nih.gov/gene/3479,,,Active,1.07734575430882,2.2132055048553068,68.66046226808844,1.83670672306008,0.162260237763032,0.758327979899895,log2_fold_induction,2,0.486780713289096,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.79597403059001,1.79597403059001,1.37362031822205,20,growth factor
LTEA_HepaRG_PEG10_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001165908.1,PEG10,paternally expressed 10,https://www.ncbi.nlm.nih.gov/gene/23089,,,Active,0.857861338041293,1.262400675189017,14.942906858835418,1.17443508944409,0.226515863756396,0.695396304785961,log2_fold_induction,2,0.679547591269188,"[""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active"",""Borderline active""]",2.03692300562588,2.03692300562588,-0.242041646246316,20,dna binding
LTEA_HepaRG_SULT2A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_003158.2,SULT2A1,"sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1",https://www.ncbi.nlm.nih.gov/gene/6822,,,Active,0.928233510145513,1.6539515880869953,14.958773721629779,1.17489599274248,0.187073897614124,0.802853735440127,log2_fold_induction,2,0.561221692842372,,1.37153588280118,1.37153588280118,0.157613992964629,20,transferase
LTEA_HepaRG_THRSP_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003242.1,THRSP,thyroid hormone responsive,https://www.ncbi.nlm.nih.gov/gene/7069,,,Active,2.03559522473244,2.0946163696874653,72.18824990411623,1.85846651312241,0.323940818661091,1.49877615623854,log2_fold_induction,2,0.971822455983273,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.84598925945172,1.84598925945172,1.55521287167747,20,growth factor
LTEA_HepaRG_UGT1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000454.1,UGT1A1,"UDP glucuronosyltransferase 1 family, polypeptide A1",https://www.ncbi.nlm.nih.gov/gene/54658,,,Active,1.42438514180858,2.150546339971104,6.529275305501178,0.814864980924769,0.220778803248623,1.61142236957257,log2_fold_induction,1.47712125471966,0.662336409745869,,0.784805574752561,0.784805574752561,0.343895768473715,20,transferase
LTEA_HepaRG_UGT1A6_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001063.2,UGT1A6,"UDP glucuronosyltransferase 1 family, polypeptide A6",https://www.ncbi.nlm.nih.gov/gene/54578,,,Active,0.619461735928341,1.0982945778529198,0.04422115288853353,-1.3543699391295,0.188007160804812,0.655763504767871,log2_fold_induction,-1,0.564021482414436,"[""Borderline active"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",-1.22843577449013,-1.22843577449013,-1.47365059366635,20,transferase
NVS_NR_cAR,"Data from the assay component NVS_NR_cAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_cAR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_001009012.1,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/747460,,,Active,84.4811485446151,4.224057427230755,21.920974541557033,1.34085985768699,2.67547881471795,70.4009571212422,percent_activity,1.69897000433602,20,,1.05624929904544,0.792869123480047,0.806662346765604,20,nuclear receptor
OT_AR_ARSRC1_0480,"Data from the assay component OT_AR_ARSRC1_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_005408.1,"AR | SRC","androgen receptor , SRC proto-oncogene, non-receptor tyrosine kinase","https://www.ncbi.nlm.nih.gov/gene/367 , https://www.ncbi.nlm.nih.gov/gene/6714",,,Active,126.666666562081,6.33333332810405,58.662892042961815,1.76836346961179,2.45637869822485,90.4761904761905,percent_activity,2,20,,1.33988654937771,1.05567905006607,1.20595410611654,20,nuclear receptor
OT_AR_ARSRC1_0960,"Data from the assay component OT_AR_ARSRC1_0960 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARSRC1_0960, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_005408.1,"AR | SRC","androgen receptor , SRC proto-oncogene, non-receptor tyrosine kinase","https://www.ncbi.nlm.nih.gov/gene/367 , https://www.ncbi.nlm.nih.gov/gene/6714",,,Active,80.5398772901184,4.02699386450592,37.325239123810654,1.57200259870969,1.6382320441989,66.1349693251534,percent_activity,2,20,,1.09897889693351,0.404547380975996,0.633606560281458,20,nuclear receptor
OT_ERa_EREGFP_0120,"Data from the assay component OT_ERa_GFPERaERE_0120 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ERa_EREGFP_0120, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,43.0360531011537,2.151802655057685,17.000568379905076,1.23046344138592,0.488098765432099,34.1555977229602,percent_activity,1.47712125471966,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.20354678034388,0.593192422966986,0.811991176617469,20,nuclear receptor
OT_ER_ERaERa_0480,"Data from the assay component OT_ER_ERaERa_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERa_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,"[30,200,29,165,53,52,167,112,30,67,200,29,165,53,52,67,112,167]",[1181],Active,118.910806747938,5.9455403373969,102.48283931203125,2.01065114913774,1.66499024557606,58.4848250431912,percent_activity,2,20,,1.66749459588791,1.33935336224485,1.53895987072166,20,nuclear receptor
OT_ER_ERaERa_1440,"Data from the assay component OT_ER_ERaERa_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERa_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,"[200,29,165,53,52,30,67,112,167,200,29,165,53,52,167,112,30,67]",[1181],Active,84.961003225088,4.2480501612544,73.75662718595159,1.86780104866351,0.639607305334083,64.8577421610284,percent_activity,2,20,,1.73722918992413,1.45020810263176,1.62426765694195,20,nuclear receptor
OT_ER_ERaERb_0480,"Data from the assay component OT_ER_ERaERb_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERb_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".","NP_000116.2|NP_001428.1","ESR1 | ESR2","estrogen receptor 1 , estrogen receptor 2 (ER beta)","https://www.ncbi.nlm.nih.gov/gene/2099 , https://www.ncbi.nlm.nih.gov/gene/2100",,,Active,152.561092997809,6.547756126660551,38.058444594867744,1.58045103519458,4.65995037220843,116.129506990434,percent_activity,2,23.2997518610421,,0.966655135886785,0.758719579662949,0.79333038812934,20,nuclear receptor
OT_ER_ERaERb_1440,"Data from the assay component OT_ER_ERaERb_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERb_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".","NP_000116.2|NP_001428.1","ESR1 | ESR2","estrogen receptor 1 , estrogen receptor 2 (ER beta)","https://www.ncbi.nlm.nih.gov/gene/2099 , https://www.ncbi.nlm.nih.gov/gene/2100",,,Active,626.542909923489,31.32714549617445,60.90999142104542,1.7846885383326,1.91268599454975,517.835213479937,percent_activity,2,20,"[""Noisy data"",""Noisy data""]",1.31865795782726,1.14494319380054,1.48458277045893,20,nuclear receptor
OT_ER_ERbERb_0480,"Data from the assay component OT_ER_ERbERb_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERbERb_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_001428.1,ESR2,estrogen receptor 2 (ER beta),https://www.ncbi.nlm.nih.gov/gene/2100,,,Active,72.7070584810137,3.635352924050685,20.46036259881593,1.31091332601688,3.03794948946985,62.5855124352663,percent_activity,2,20,,0.969512227482482,0.626463195816782,0.5367939873047,20,nuclear receptor
OT_ER_ERbERb_1440,"Data from the assay component OT_ER_ERbERb_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERbERb_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_001428.1,ESR2,estrogen receptor 2 (ER beta),https://www.ncbi.nlm.nih.gov/gene/2100,,,Active,42.3270485234498,2.1163524261724898,10.708534038109315,1.02973002146341,1.48426296250401,43.4807896267406,percent_activity,1.47712125471966,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.02375485622655,0.913516012381499,0.910449704475529,20,nuclear receptor
OT_FXR_FXRSRC1_0480,"Data from the assay component OT_FXR_FXRSRC1_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_FXR_FXRSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".","NP_005408.1|NP_001193922.1","SRC | NR1H4","SRC proto-oncogene, non-receptor tyrosine kinase , nuclear receptor subfamily 1, group H, member 4","https://www.ncbi.nlm.nih.gov/gene/6714 , https://www.ncbi.nlm.nih.gov/gene/9971",,,Active,265.683253029782,10.600342411268636,45.528750247316815,1.65828572919808,5.01272964064537,264.034668949396,percent_activity,2,25.0636482032268,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.5354905048781,1.50554110404126,1.53899629949743,20,nuclear receptor
OT_FXR_FXRSRC1_1440,"Data from the assay component OT_FXR_FXRSRC1_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_FXR_FXRSRC1_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".","NP_005408.1|NP_001193922.1","SRC | NR1H4","SRC proto-oncogene, non-receptor tyrosine kinase , nuclear receptor subfamily 1, group H, member 4","https://www.ncbi.nlm.nih.gov/gene/6714 , https://www.ncbi.nlm.nih.gov/gene/9971",,,Active,251.153103943951,6.034125852331694,50.95558338975191,1.70719177818554,8.32442378863878,248.444762245263,percent_activity,2,41.6221189431939,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.61833879711056,1.58605276730471,1.58639909501619,20,nuclear receptor
OT_NURR1_NURR1RXRa_0480,"Data from the assay component OT_NURR1_NURR1RXRa_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_NURR1_NURR1RXRa_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene RXRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".","NP_006177.1|NP_002948.1","NR4A2 | RXRA","nuclear receptor subfamily 4, group A, member 2 , retinoid X receptor, alpha","https://www.ncbi.nlm.nih.gov/gene/4929 , https://www.ncbi.nlm.nih.gov/gene/6256",,,Active,60.0407576832404,2.972718916559752,39.40501868843182,1.59555153781259,4.03945070950227,58.8310502283105,percent_activity,2,20.1972535475113,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.55855908284973,1.52069346989578,1.47591773495293,20,nuclear receptor
OT_NURR1_NURR1RXRa_1440,"Data from the assay component OT_NURR1_NURR1RXRa_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_NURR1_NURR1RXRa_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene RXRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".","NP_006177.1|NP_002948.1","NR4A2 | RXRA","nuclear receptor subfamily 4, group A, member 2 , retinoid X receptor, alpha","https://www.ncbi.nlm.nih.gov/gene/4929 , https://www.ncbi.nlm.nih.gov/gene/6256",,,Active,160.099115473203,6.209567129096372,84.20670267911478,1.92534666181673,5.15653062910042,128.240452960731,percent_activity,2,25.7826531455021,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.83574645643852,1.80399939867327,1.8060663474013,20,nuclear receptor
TOX21_AP1_BLA_Agonist_ch1,"Data from the assay component TOX21_AP1_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,68.9826369551298,3.4491318477564903,29.57448198033913,1.47091714636673,2.57591984669775,70.1786713026,percent_activity,1.90308998699194,20,,1.42229062563747,1.35853126195786,1.35163683266861,20,channel 1
TOX21_AP1_BLA_Agonist_ratio,"Data from the assay component TOX21_AP1_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_002219.1,"JUN | FOS|JUN","jun proto-oncogene , FBJ murine osteosarcoma viral oncogene homolog|jun proto-oncogene","https://www.ncbi.nlm.nih.gov/gene/3725 , https://www.ncbi.nlm.nih.gov/gene/4029",,,Active,37.3538827184499,1.8676941359224952,37.69846482742814,1.57632366504527,2.7369041511147,36.9210108635,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.5840278322512,1.50755417116692,1.45704335127497,20,dna binding
TOX21_AP1_BLA_Agonist_viability,"TOX21_AP1_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle target family, where the subfamily is cytotoxicity.",, , , ,,,Active,56.1663584515919,2.4895758645147303,32.10860497388844,1.506621437136,3.76010222277627,55.4972422971,percent_activity,1.90308998699194,22.5606133366576,,1.48498860866412,1.43164762429373,1.38734112282095,20,cell cycle
TOX21_AR_BLA_Antagonist_ratio,"Data from the assay component TOX21_AR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,"[307,19,23,111,187,117,307,111,19,23,187,117]",,Active,28.7591283287117,1.1022015052983254,29.559122461321788,1.47069153676397,4.34874025461246,29.4625161167,percent_activity,1.90308998699194,26.0924415276748,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.59450937568718,1.46059505767109,1.35141122262195,20,nuclear receptor
TOX21_ARE_BLA_agonist_ratio,"Data from the assay component TOX21_ARE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_ARE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.  ",NP_006155.2,NFE2L2,"nuclear factor, erythroid 2-like 2",https://www.ncbi.nlm.nih.gov/gene/4780,"[61,61]",[478],Active,35.0011026767911,1.750055133839555,82.85800382449398,1.9183344662728,2.50978290890691,22.9107012304,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active""]",1.933947818517,1.848068340953,1.7990541469253,20,dna binding
TOX21_ARE_BLA_agonist_viability,"TOX21_ARE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,65.1499202757574,2.20116204104602,78.3428507629262,1.893999370736,4.93299441089742,48.6922159724,percent_activity,1.95424250943932,29.5979664653845,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.88404916714276,1.8275273861934,1.77471901282845,20,cell cycle
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881,"Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,66.3614008680304,2.065619320946374,6.345951299364901,0.802496734877812,5.35443940025589,66.2310934478,percent_activity,1.95424250943932,32.1266364015353,,0.786387622105447,0.513187165984308,0.245582300940222,20,nuclear receptor
TOX21_CASP3_CHO_viability,"The assay component endpoint  TOX21_CASP3_CHO_viability uses a type of viability reporter where loss-of-signal activity can be used to understand changes in viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",, , , ,,,Active,52.6320607316991,2.6316030365849548,80.7786617169332,1.90729665381335,2.57636017956492,36.7853674237,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.88071984034939,1.8117782359127,1.78801633856361,20,cell cycle
TOX21_DT40_100,"Data from the assay component TOX21_DT40_100 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_100, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability as they relate to the gene Ku70 - Rad54 (-/-). Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",,"RAD54L | XRCC6P1","RAD54 like (S. cerevisiae) , X-ray repair cross complementing 6 pseudogene 1","https://www.ncbi.nlm.nih.gov/gene/8438 , https://www.ncbi.nlm.nih.gov/gene/387703",,,Active,33.5196197958415,1.5540362495108477,46.901829009973355,1.67118977903599,3.59489896137582,34.4613347841,percent_activity,1.95424250943932,21.5693937682549,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.70324753984682,1.63070404402236,1.55190934108826,20,cell cycle
TOX21_DT40_657,"Data from the assay component TOX21_DT40_657 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_657, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene Rev3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",,REV3L,"REV3 like, DNA directed polymerase zeta catalytic subunit",https://www.ncbi.nlm.nih.gov/gene/5980,,,Active,58.7300402336932,2.241432181027727,67.82367950498073,1.83138134700742,4.36700254498032,44.6181272243,percent_activity,1.95424250943932,26.2020152698819,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.80612743163686,1.68566602512913,1.57480564368673,20,cell cycle
TOX21_ERa_LUC_VM7_Agonist,"Data from the assay component TOX21_ERa_LUC_VM7_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1.  Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,"[200,200,29,165,53,52,167,112,30,67,29,165,53,52,30,67,112,167]",[1181],Active,35.0105070127835,1.750525350639175,29.349442437735476,1.46759985520834,2.77515618820713,31.1002379842,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.51847755591736,1.26110067035905,1.0780639511801,20,nuclear receptor
TOX21_ERb_BLA_Agonist_viability,"TOX21_ERb_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,30.8947293222788,1.5034093429949127,56.40362029442791,1.75130698028535,3.42496311979521,28.4774207393,percent_activity,1.95424250943932,20.5497787187713,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.7885668911948,1.71349339236941,1.63202644298407,20,cell cycle
TOX21_ERb_BLA_Antagonist_ch2,"Data from the assay component TOX21_ERb_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,76.6393734337311,2.0949830801870837,33.9785826906159,1.53120525968659,6.09705587907717,62.8566726148,percent_activity,1.95424250943932,36.582335274463,,1.4920213356713,1.0302762187757,0.582374381263264,20,channel 2
TOX21_ERb_BLA_Antagonist_ratio,"Data from the assay component TOX21_ERb_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_001428.1,ESR2,estrogen receptor 2 (ER beta),https://www.ncbi.nlm.nih.gov/gene/2100,,,Active,78.9597216102363,3.2557302167341113,33.73555193295526,1.52808781985595,4.04208970819059,58.8519871056,percent_activity,1.95424250943932,24.2525382491435,,1.19470213400256,0.828578369428389,0.62759996740882,20,nuclear receptor
TOX21_ERR_Antagonist,"Data from the assay component TOX21_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_004442.3,ESRRA,estrogen-related receptor alpha,https://www.ncbi.nlm.nih.gov/gene/2101,,,Active,48.7010425909321,2.3047255551633445,78.43758149256122,1.89452419437071,3.52182515338437,34.7226068926,percent_activity,1.95424250943932,21.1309509203062,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.88008429819677,1.82484404856757,1.77524388011015,20,nuclear receptor
TOX21_ESRE_BLA_ch1,"Data from the assay component TOX21_ESRE_BLA_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ESRE_BLA_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ATF6. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,32.5174587318095,1.579325021896759,30.294567342386824,1.48136475441777,3.43157765511288,32.3754032534,percent_activity,1.90308998699194,20.5894659306773,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.51099946904882,1.4395919736224,1.36208443884219,20,channel 1
TOX21_ESRE_BLA_ratio,"Data from the assay component TOX21_ESRE_BLA_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ESRE_BLA_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ATF6.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.",NP_031374.2,ATF6,activating transcription factor 6,https://www.ncbi.nlm.nih.gov/gene/22926,,,Active,22.215495618244,1.1107747809122,37.0934477946916,1.56929720239354,1.43781423195858,20.7511919502,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active""]",1.68874209130369,1.49203735101812,1.45001688733451,20,dna binding
TOX21_ESRE_BLA_viability,"TOX21_ESRE_BLA_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,77.0203561077793,1.729385382426835,38.75432462649906,1.58832017281983,7.42270991093352,65.7538755294,percent_activity,1.90308998699194,44.5362594656011,,1.66003039233959,1.38386983394305,1.08899538070416,20,cell cycle
TOX21_FXR_BLA_agonist_viability,"TOX21_FXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,100.60745308931,1.880861469564025,70.40664466781281,1.84761364786923,8.9150153371503,74.9122832054,percent_activity,1.90308998699194,53.4900920229018,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.85450019775971,1.79246612173266,1.72833330665355,20,cell cycle
TOX21_FXR_BLA_antagonist_ratio,"Data from the assay component TOX21_FXR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_FXR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_001193922.1,NR1H4,"nuclear receptor subfamily 1, group H, member 4",https://www.ncbi.nlm.nih.gov/gene/9971,"[27,61,27,61]",[479],Active,44.1205046351835,2.206025231759175,111.43445078644996,2.04701947695477,2.78938673282934,25.485282533,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.90946450534245,0.980693719050852,0.433614618226751,20,nuclear receptor
TOX21_GR_BLA_Agonist_ch1,"Data from the assay component TOX21_GR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,56.772527789975,2.5989029117062485,72.39306540251059,1.85969696672665,3.6408008634627,33.9206820892,percent_activity,1.90308998699194,21.8448051807762,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.8107979254799,1.71022742261664,1.63076425854436,20,channel 1
TOX21_H2AX_HTRF_CHO_Agonist_ratio,"Data from the assay component TOX21_H2AX_HTRF_CHO_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_H2AX_HTRF_CHO_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene H2AFX. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is histone.",NP_002096.1,H2AFX,"H2A histone family, member X",https://www.ncbi.nlm.nih.gov/gene/3014,,,Active,34.9950774132083,1.749753870660415,170.69949511789602,2.23223223659314,1.1538473582706,27.1820715237,percent_activity,2.30102999566398,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",2.24786739714272,2.11229435459406,2.11295192204377,20,dna binding
TOX21_H2AX_HTRF_CHO_viability,"TOX21_H2AX_HTRF_CHO_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,33.0607454707355,1.6530372735367749,74.12037984077939,1.86993763625846,2.15763115046871,29.970716946,percent_activity,2.30102999566398,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.93200448989666,1.66415108076542,1.54989991559361,20,cell cycle
TOX21_HRE_BLA_Agonist_ch1,"Data from the assay component TOX21_HRE_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HRE_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HIF1A. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,79.7846412537185,3.9892320626859252,61.618924703745726,1.789714115284,2.28898316931438,60.961043649,percent_activity,1.90308998699194,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.68615856504988,1.5662823124476,1.58192291204103,20,channel 1
TOX21_HRE_BLA_Agonist_ratio,"Data from the assay component TOX21_HRE_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HRE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HIF1A. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is hypoxia-response element.",NP_001521.1,HIF1A,"hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)",https://www.ncbi.nlm.nih.gov/gene/3091,,,Active,60.9672179518209,3.048360897591045,77.19791102592525,1.88760554849392,0.3624938875215,33.0796952663,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.80296212077142,1.41442276669943,1.62823279001526,20,dna binding
TOX21_HRE_BLA_Agonist_viability,"TOX21_HRE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,32.1605629768204,1.60802814884102,46.712640184952676,1.66943441418036,3.0508964104962,30.4900319458,percent_activity,1.90308998699194,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.69644395354467,1.61939344296905,1.55015410025607,20,cell cycle
TOX21_MMP_ratio_down,"Data from the assay component TOX21_MMP_ratio was analyzed into 2 assay endpoints. This assay endpoint, TOX21_MMP_ratio_down, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of 6 membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.",, , , ,,,Active,96.2458065941261,2.4893185640364615,29.54057204285754,1.47041890101828,6.44391923052108,79.9360685152,percent_activity,1.95424250943932,38.6635153831265,,1.28539435328238,0.828953434743941,0.449777619494113,20,cell morphology
TOX21_NFkB_BLA_agonist_ch1,"Data from the assay component TOX21_NFkB_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_NFkB_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFKB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,69.0736049309102,3.4536802465455096,42.57905441528909,1.62919601250902,3.27484652838546,62.3664900503,percent_activity,1.90308998699194,20,,1.52274000922605,1.41608373050779,1.36860042067746,20,channel 1
TOX21_NFkB_BLA_agonist_viability,"TOX21_NFkB_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,49.2735099184762,2.0079082780074735,32.4075894439608,1.51064672834414,4.08995358155937,44.585522125,percent_activity,1.90308998699194,24.5397214893562,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.51021910182828,1.45072111277646,1.39136641379289,20,cell cycle
TOX21_p53_BLA_p1_ch1,"Data from the assay component TOX21_p53_BLA_p1_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,46.4070033531775,2.320350167658875,53.31740700253349,1.72686902011402,3.00976293237186,45.9297526327,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.71178287908051,1.64974911808272,1.60758870313385,20,channel 1
TOX21_p53_BLA_p1_ratio,"Data from the assay component TOX21_p53_BLA_p1_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",NP_000537.3,TP53,tumor protein p53,https://www.ncbi.nlm.nih.gov/gene/7157,"[46,46]",,Active,38.6527956749008,1.93263978374504,62.8855530175581,1.79855088446904,1.19928273802848,36.5682208493,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.80233664291278,1.67496255439142,1.67927055179128,20,dna binding
TOX21_p53_BLA_p1_viability,"TOX21_p53_BLA_p1_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,91.8827494980324,2.190156172067821,64.4275056739155,1.80907131785847,6.99210027956454,66.8087726466,percent_activity,1.95424250943932,41.9526016773872,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.78511497163226,1.64146271461414,1.50670400793742,20,cell cycle
TOX21_p53_BLA_p2_ch1,"Data from the assay component TOX21_p53_BLA_p2_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,74.1192216657423,3.7059610832871153,63.67479733748755,1.80396757137651,2.8966141715805,61.7660400556,percent_activity,1.95424250943932,20,,1.71092185216501,1.61526809848781,1.59859224057826,20,channel 1
TOX21_p53_BLA_p2_ratio,"Data from the assay component TOX21_p53_BLA_p2_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",NP_000537.3,TP53,tumor protein p53,https://www.ncbi.nlm.nih.gov/gene/7157,"[46,46]",,Active,37.2122851626426,1.86061425813213,73.61562914034614,1.86697002804435,0.95929146331389,31.0102402153,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.87511896092875,1.73238780749885,1.74768971435084,20,dna binding
TOX21_p53_BLA_p2_viability,"TOX21_p53_BLA_p2_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,78.8010002100625,2.2328974682091,52.56058804915663,1.72066021547629,5.8818195738939,65.6675001951,percent_activity,1.95424250943932,35.2909174433634,,1.68846939572111,1.52955411757622,1.38283028723469,20,cell cycle
TOX21_p53_BLA_p3_ch1,"Data from the assay component TOX21_p53_BLA_p3_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p3_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,33.2154406579925,1.6170357508193682,73.73978804991526,1.86770188498037,3.42349065166122,27.6795339263,percent_activity,1.95424250943932,20.5409439099673,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.89391309415614,1.82406475118757,1.74842157071603,20,channel 1
TOX21_p53_BLA_p3_viability,"TOX21_p53_BLA_p3_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,42.5735383863926,1.412491014918077,42.01279871711098,1.62338161338546,5.02345831309728,35.47794873,percent_activity,1.95424250943932,30.1407498785837,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",1.82492265700398,1.48646972146961,1.12331328604684,20,cell cycle
TOX21_p53_BLA_p5_ch1,"Data from the assay component TOX21_p53_BLA_p5_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,35.3843304716758,1.5092276419422117,73.91149911703546,1.86871201098715,3.90755393557242,29.4869425666,percent_activity,1.95424250943932,23.4453236134345,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.90534801480297,1.83058461933252,1.74943169707874,20,channel 1
TOX21_PPARd_BLA_Agonist_viability,"TOX21_PPARd_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,100.192063958906,3.0047823294487146,63.10016165401393,1.80003047184883,5.55736672264977,82.6366079124,percent_activity,1.90308998699194,33.3442003358986,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.74728401878289,1.67783261653862,1.63340230614973,20,cell cycle
TOX21_PPARg_BLA_antagonist_viability,"TOX21_PPARg_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,112.454895116359,2.052567998758255,80.41444736279854,1.9053340816623,9.1312358619699,55.0412155854,percent_activity,1.90308998699194,54.7874151718194,"[""Borderline active"",""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active""]",1.90255281133609,1.84382400178352,1.78605376482068,20,cell cycle
TOX21_PR_BLA_Agonist_ratio,"Data from the assay component TOX21_PR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000917.3,PGR,progesterone receptor,https://www.ncbi.nlm.nih.gov/gene/5241,,,Active,27.7274588461973,1.386372942309865,65.2313627997407,1.8144564518051,0.84515254329408,20.4139205374,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.94845802475028,1.49089862188251,1.50483884096763,20,nuclear receptor
TOX21_PR_BLA_Agonist_viability,"TOX21_PR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,86.0696084265769,2.5893161339235538,80.27270516372606,1.90456789880439,5.54004764031117,60.275775202,percent_activity,1.95424250943932,33.240285841867,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.87941661218382,1.82693862928859,1.78528758464122,20,cell cycle
TOX21_PR_BLA_Antagonist_ch1,"Data from the assay component TOX21_PR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,55.5460665817786,1.9498444371751635,26.31468345845537,1.4201981502198,4.74790582629342,36.4440817467,percent_activity,1.60205999132796,28.4874349577605,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.4350965316875,1.11196311245902,0.784034888893256,20,channel 1
TOX21_PR_BLA_Antagonist_ch2,"Data from the assay component TOX21_PR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,69.7083912417648,1.6779010571925983,11.752890093268906,1.07014467488199,6.92416585421295,67.8089478608,percent_activity,1.60205999132796,41.5449951252777,,1.13656455929303,0.92374370042869,0.694741651788457,20,channel 2
TOX21_PR_BLA_Antagonist_ratio,"Data from the assay component TOX21_PR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity an be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000917.3,PGR,progesterone receptor,https://www.ncbi.nlm.nih.gov/gene/5241,,,Active,72.0890534361825,3.604452671809125,11.479877878787622,1.05993726812722,2.51198214229767,70.8877789606,percent_activity,1.60205999132796,20,,0.83823634075432,0.562487536296024,0.551041266559771,20,nuclear receptor
TOX21_PR_BLA_Followup_Agonist_ch2,"Data from the assay component TOX21_PR_BLA_Followup_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,20.0667332106035,1.8513865215470584,51.87769140172972,1.71498064139435,3.61291982649402,15.3503571162,percent_activity,1.95424250943932,10.83875947948206,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.7655379206548971,1.7655379206548971,1.0245315899001919,20,channel 2
TOX21_PR_BLA_Followup_Antagonist_ch1,"Data from the assay component TOX21_PR_BLA_Followup_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,35.2663382786758,1.229395655743898,28.339879671850714,1.45239800194665,9.56197139461893,36.3274904412,percent_activity,1.95424250943932,28.685914183856788,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.5323254373149515,1.5323254373149515,1.3331168167246343,20,channel 1
TOX21_PR_BLA_Followup_Antagonist_ratio,"Data from the assay component TOX21_PR_BLA_Followup_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000917.3,PGR,progesterone receptor,https://www.ncbi.nlm.nih.gov/gene/5241,,,Active,91.0105471108039,1.8870815836627512,24.348711883456982,1.38647599073735,8.03803325186715,84.5016594234,percent_activity,1.95424250943932,48.2281995112029,,1.4098580188394496,1.1873592654152085,0.9576971097486968,20,nuclear receptor
TOX21_PR_LUC_Followup_Antagonist,"Data from the assay component TOX21_PR_LUC_Followup_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_LUC_Followup_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is steroidal.",NP_000917.3,PGR,progesterone receptor,https://www.ncbi.nlm.nih.gov/gene/5241,,,Active,100.609139179855,2.029894146448404,32.12928449293935,1.50690105408472,8.26062279781809,76.7281177458,percent_activity,1.95424250943932,49.5637367869085,,1.49529841500758,1.06638807998613,0.641420989305909,20,nuclear receptor
TOX21_PXR_Agonist,"Data from the assay component TOX21_PXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PXR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is non-steroidal.",NP_071285.1,NR1I2,"nuclear receptor subfamily 1, group I, member 2",https://www.ncbi.nlm.nih.gov/gene/8856,,,Active,84.7839464831097,4.2391973241554854,56.83571128143934,1.7546212994265,1.80636679455099,60.5441074007,percent_activity,1.95424250943932,20,,1.48915365905456,1.14836500598067,1.25834006132885,20,nuclear receptor
TOX21_PXR_viability,"The assay component endpoint  TOX21_PXR_viability was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",, , , ,,,Active,35.9653634357578,1.7982681717878901,76.37895896710708,1.88297373471389,2.43196946437473,28.4893519436,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.89520513301882,1.80868122649619,1.76369342097402,20,cell cycle
TOX21_RAR_LUC_Agonist_viability,"TOX21_RAR_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,74.5129478435677,3.7256473921783853,83.34100365655593,1.9208587262614,1.53553439731881,41.7103761876,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.77063009610031,1.51338968042245,1.5916634819564,20,cell cycle
TOX21_RORg_LUC_CHO_Antagonist,"Data from the assay component TOX21_RORg_LUC_CHO_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RORg_LUC_CHO_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1F3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_005051.2,RORC,RAR-related orphan receptor C,https://www.ncbi.nlm.nih.gov/gene/6097,,,Active,70.5805857164357,1.354577220470924,54.860474430670756,1.73925955904196,8.68420845631059,58.5998455801,percent_activity,1.95424250943932,52.1052507378635,"[""Borderline active"",""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active""]",1.89656563923103,1.65793867101844,1.40590011109014,20,nuclear receptor
TOX21_RORg_LUC_CHO_Antagonist_viability,"TOX21_RORg_LUC_CHO_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,59.1661544963508,2.95830772481754,69.7576124445283,1.84359160782028,3.0881472477345,41.3182000451,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.75400343794284,1.61913197503057,1.5507021820735,20,cell cycle
TOX21_RT_HEK293_FLO_08hr_viability,"TOX21_RT_HEK293_FLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,153.080024180323,6.500034732912482,65.43361812634464,1.81580093510598,3.92510785122456,127.5666874509,percent_activity,1.90308998699194,23.5506471073474,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.72325525597372,1.68090296491765,1.69652062126975,20,cell cycle
TOX21_RT_HEK293_FLO_16hr_viability,"TOX21_RT_HEK293_FLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,241.758860551562,9.640747609583123,62.625752693596546,1.79675295865512,4.17946253309319,201.4659894588,percent_activity,1.90308998699194,25.0767751985591,,1.65426494744775,1.60474902323641,1.65157338921281,20,cell cycle
TOX21_RT_HEK293_FLO_24hr_viability,"TOX21_RT_HEK293_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,271.527331916838,10.108110940690134,65.42746791898742,1.81576011317487,4.47705368342379,226.2727766263,percent_activity,1.90308998699194,26.8623221005427,,1.69583157400659,1.65530161234042,1.69647979931117,20,cell cycle
TOX21_RT_HEK293_FLO_32hr_viability,"TOX21_RT_HEK293_FLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,279.349461682305,9.825897268508198,65.4275444343563,1.81576062106833,4.73831980341741,232.7912993076,percent_activity,1.90308998699194,28.4299188205045,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.69754076247354,1.65692054310649,1.69648030729894,20,cell cycle
TOX21_RT_HEK293_FLO_40hr_viability,"TOX21_RT_HEK293_FLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,46.396944449961,1.625795708529405,34.877170527062056,1.54254124477178,4.75633195144065,41.7034375527,percent_activity,1.90308998699194,28.5379917086439,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.62021004541728,1.40805290991589,1.17846102285336,20,cell cycle
TOX21_RT_HEK293_GLO_08hr_viability,"TOX21_RT_HEK293_GLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,49.9372277839659,2.056824673690453,35.53970607506775,1.55071383172747,4.04646609105207,49.8593796483,percent_activity,1.90308998699194,24.2787965463124,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.54771346367018,1.48905511835681,1.43143351676413,20,cell cycle
TOX21_RT_HEK293_GLO_16hr_viability,"TOX21_RT_HEK293_GLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,39.4386562310836,1.6360343474072534,35.845637981287936,1.55443631437158,4.0177086637968,39.0552617118,percent_activity,1.90308998699194,24.1062519827808,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.58856038965856,1.49254649199297,1.3887395020572,20,cell cycle
TOX21_RT_HEK293_GLO_24hr_viability,"TOX21_RT_HEK293_GLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,37.4583994214298,1.5267229801703575,37.77790490087568,1.57723786901147,4.08919407864135,37.3648650159,percent_activity,1.90308998699194,24.5351644718481,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.61204008599717,1.53817745891356,1.45795755434466,20,cell cycle
TOX21_RT_HEK293_GLO_32hr_viability,"TOX21_RT_HEK293_GLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,34.9573514316539,1.3914814271679903,44.207690554632926,1.64549782760488,4.18706647811088,34.6555314956,percent_activity,1.90308998699194,25.1223988686653,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.69640893606558,1.61410503833271,1.52621750496895,20,cell cycle
TOX21_RT_HEK293_GLO_40hr_viability,"TOX21_RT_HEK293_GLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,61.452848477465,2.467453363852153,58.94749924327898,1.77046538554847,4.15089564121323,51.2107105287,percent_activity,1.90308998699194,24.9053738472794,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.73878483282056,1.65730877844308,1.58896833808955,20,cell cycle
TOX21_RT_HEPG2_FLO_24hr_viability,"TOX21_RT_HEPG2_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,40.6583933381425,1.4822578543891891,0.07431822203250821,-1.12890468882479,4.57167345723585,33.8820045978,percent_activity,-1,27.4300407434151,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Cell viability assay fit with gnls winning model"",""Cell viability assay fit with gnls winning model"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",-1.07040689969456,-1.18306849707878,-1.30515170642684,20,cell cycle
TOX21_RT_HEPG2_FLO_32hr_ctrl_viability,"TOX21_RT_HEPG2_FLO_32hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,54.2141911874633,1.8515293257562448,0.07060202667888554,-1.15118283205268,4.88012714978376,51.0616640238,percent_activity,-1,29.2807628987026,"[""Cell viability assay fit with gnls winning model"",""Cell viability assay fit with gnls winning model""]",-1.14245765213165,-1.20516557663519,-1.27046493759375,20,cell cycle
TOX21_RT_HEPG2_FLO_40hr_ctrl_viability,"TOX21_RT_HEPG2_FLO_40hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,70.8418848722528,2.6307326306568104,0.0730017395565209,-1.13666679096452,4.48809608184861,65.5487475293,percent_activity,-1,26.9285764910917,"[""Cell viability assay fit with gnls winning model"",""Cell viability assay fit with gnls winning model""]",-1.16322655808573,-1.21539699983008,-1.25600067030619,20,cell cycle
TOX21_RXR_BLA_Agonist_viability,"TOX21_RXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,88.2502404268958,3.313908974773359,30.812882078132933,1.48873232188365,4.43837580224682,87.4396629112,percent_activity,1.90308998699194,26.6302548134809,,1.44318743238369,1.39493651008328,1.36944780283772,20,cell cycle
TOX21_TR_LUC_GH3_Antagonist,"Data from the assay component TOX21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_003241.2|NP_000452.2","THRA | THRB","thyroid hormone receptor, alpha , thyroid hormone receptor, beta","https://www.ncbi.nlm.nih.gov/gene/7067 , https://www.ncbi.nlm.nih.gov/gene/7068",,,Active,121.90227017724,5.433153642533786,50.186787692576075,1.70058939867,3.73945711206963,117.4686320409,percent_activity,1.95424250943932,22.4367426724178,,1.57052654654171,1.50065120205418,1.50867808095779,20,nuclear receptor
TOX21_TR_LUC_GH3_Antagonist_viability,"TOX21_TR_LUC_GH3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,94.3490578791651,2.354291821188034,48.55957245064533,1.68627485427925,6.67922423139783,97.8321038039,percent_activity,1.95424250943932,40.075345388387,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.66981081935424,1.61512383166924,1.56699451912762,20,cell cycle
TOX21_TSHR_HTRF_Antagonist_ch1,"Data from the assay component TOX21_TSHR_HTRF_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,31.207306089494,1.5603653044747001,27.005953894925863,1.43145952188702,1.90228676304723,30.5718660627,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.52136203610033,1.19907986505061,1.09038997585671,20,channel 1
TOX21_TSHR_HTRF_Antagonist_ratio,"Data from the assay component TOX21_TSHR_HTRF_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this one serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.",,TSHR,thyroid stimulating hormone receptor,https://www.ncbi.nlm.nih.gov/gene/7253,,,Active,31.8520758788912,1.5926037939445599,27.980707039430794,1.44685868440326,1.7350029827067,30.6729167951,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.5488641107802,1.12848820718556,1.01850183426767,20,gpcr
TOX21_VDR_BLA_Agonist_viability,"TOX21_VDR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,64.5094049185909,2.3725420244929145,31.65880587413793,1.50049452985505,4.53166577259249,63.0321102093,percent_activity,1.90308998699194,27.1899946355549,,1.48330382345022,1.42881183339953,1.38121421558178,20,cell cycle
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist,"Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist was analyzed into 1 assay endpoint. 
This assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist, was analyzed in the positive fitting direction relative to DHT as the baseline of activity. 
Using a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,90.880804005766,2.393011266456588,15.118578463540134,1.17951095819802,12.6591971211703,74.6620938012356,percent_activity,2,37.9775913635109,,0.949462522853389,0.949462522853389,-0.345427821794556,20.000499725341797,nuclear receptor
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist,"Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist was analyzed into 1 assay endpoint. 
This assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist, was analyzed in the positive fitting direction relative to DHT as the baseline of activity. 
Using a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,67.4599867074594,1.0620004133459555,14.159944544921373,1.15106155251464,21.1738733368031,64.6655014957086,percent_activity,2,63.5216200104093,"[""Borderline active"",""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active""]",2.05569334497087,2.05569334497087,0.436226970838265,20.000499725341797,nuclear receptor